No
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-111
|
82-28-0 |
1-Amino-2-methylanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 16/50 27/50; SQUAMOUS CELL CARCINOMA 0/50 12/50 11/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/51 16/50; SQUAMOUS CELL CARCINOMA 0/50 12/51 13/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 28/40 53/60 43/49; CARCINOMA 0/50 2/40 21/60 8/49
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 13/40 51/59 40/50; CARCINOMA 0/50 1/40 11/59 17/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 3/40 16/60 16/48 OR CARCINOMA 0/50 0/40 0/60 2/48
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 10/40 11/59 14/50 OR CARCINOMA 0/50 0/40 2/59 1/50
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 45/50 49/50; CARCINOMA 0/50 23/50 27/50
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 38/51 39/50; CARCINOMA 9/50 18/51 21/50
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 28/40 47/60 29/48; CARCINOMA 0/50 12/40 57/60 45/48; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 11/60 13/48
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 20/40 40/59 34/50; CARCINOMA 1/50 12/40 55/59 46/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 6/59 2/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 17/50 13/49
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/50 26/51 24/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 2/40 7/60 9/46; TRANSITIONAL CELL CARCINOMA 0/50 0/40 8/60 16/46
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 1/38 2/58 8/50; TRANSITIONAL CELL CARCINOMA 0/50 0/38 1/58 4/50
|
Neoplastic Lesions
|
No
|
TR-237
|
630-20-6 |
1,1,1,2-Tetrachloroethane |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-237
|
630-20-6 |
1,1,1,2-Tetrachloroethane |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal |
NEOPLASTIC NODULE 0/49 1/49 2/48 OR CARCINOMA 0/49 0/49 1/48 COMBINED 0/49 1/49 3/48
|
Neoplastic Lesions
|
Yes
|
TR-237
|
630-20-6 |
1,1,1,2-Tetrachloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
ADENOMA 4/49 8/46 24/48 OR CARCINOMA 1/49 5/46 6/48 COMBINED 5/49 13/46 30/48
|
Neoplastic Lesions
|
Yes
|
TR-237
|
630-20-6 |
1,1,1,2-Tetrachloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
ADENOMA 6/48 14/46 21/50
|
Neoplastic Lesions
|
No
|
TR-074
|
79-00-5 |
1,1,2-Trichloroethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-074
|
79-00-5 |
1,1,2-Trichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-074
|
79-00-5 |
1,1,2-Trichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Adrenal Gland Medulla
|
Positive |
Positive |
PHEOCHROMOCYTOMA
|
Neoplastic Lesions
|
No
|
TR-074
|
79-00-5 |
1,1,2-Trichloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Adrenal Gland Medulla
|
Positive |
Positive |
PHEOCHROMOCYTOMA
|
Neoplastic Lesions
|
Yes
|
TR-074
|
79-00-5 |
1,1,2-Trichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-074
|
79-00-5 |
1,1,2-Trichloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-027
|
79-34-5 |
1,1,2,2-Tetrachloroethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-027
|
79-34-5 |
1,1,2,2-Tetrachloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-027
|
79-34-5 |
1,1,2,2-Tetrachloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-027
|
79-34-5 |
1,1,2,2-Tetrachloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-263
|
78-87-5 |
1,2-Dichloropropane (propylene dichloride) |
Rats |
F344/N |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-263
|
78-87-5 |
1,2-Dichloropropane (propylene dichloride) |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 5/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-263
|
78-87-5 |
1,2-Dichloropropane (propylene dichloride) |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 7/50 10/50 17/50
|
Neoplastic Lesions
|
No
|
TR-263
|
78-87-5 |
1,2-Dichloropropane (propylene dichloride) |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Equivocal Evidence |
Equivocal Evidence |
ADENOCARCINOMA 1/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 6/50 7/51 10/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/52 2/51 10/54 11/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/49 0/47 1/52 2/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 0/50 2/48 1/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 20/49 21/52
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/50 6/49 12/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 21/50 36/49 29/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 1/59 0/60 4/60
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 0/60 0/59 3/60
|
Neoplastic Lesions
|
No
|
TR-198
|
57653-85-7 |
1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin |
Rats |
Osborne Mendel |
Male |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal |
(NEOPLASTIC NODULE OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-198
|
57653-85-7 |
1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-198
|
57653-85-7 |
1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-198
|
57653-85-7 |
1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin |
Rats |
Osborne Mendel |
Female |
Gavage |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Equivocal Evidence |
GLIOMA 0/50 2/48 1/49
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 4/42 10/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 5/40 0/44
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 1/50 10/49 10/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 0/50 23/50 29/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
|
Neoplastic Lesions
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
|
Neoplastic Lesions
|
Yes
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/47 4/49 OR CARCINOMA 0/50 1/47 1/49 COMBINED 0/50 2/47 5/49
|
Neoplastic Lesions
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 9/48 20/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 6/48 8/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 12/49 11/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 5/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ACINAR CELL CARCINOMA 0/50 2/49 6/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
GRANULOSA CELL TUMOR 0/49 6/45 12/48
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 0/50 3/50 1/50
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 11/48 18/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 16/49 7/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
(STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
|
May Have Been Related
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/52 1/52 9/52; SQUAMOUS CELL CARCINOMA 0/52 0/52 4/52
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 2/52 3/52
|
Neoplastic Lesions
|
Yes
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/52 6/52 7/52
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 8/50
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL CARCINOMA 0/50 8/50 21/48
|
Neoplastic Lesions
|
No
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Mice |
B6C3F1 |
Male |
Gavage |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 0/47 2/48 4/49
|
May Have Been Related
|
No
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/50 3/50 7/50
|
Neoplastic Lesions
|
Yes
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 6/48 21/50; CARCINOMA 5/50 5/48 19/50
|
Neoplastic Lesions
|
Yes
|
TR-319
|
106-46-7 |
1,4-Dichlorobenzene (p-dichlorobenzene) |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 13/49 16/50; CARCINOMA 14/50 11/49 32/50
|
Neoplastic Lesions
|
Yes
|
TR-080
|
123-91-1 |
1,4-Dioxane |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-080
|
123-91-1 |
1,4-Dioxane |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-080
|
123-91-1 |
1,4-Dioxane |
Rats |
Osborne Mendel |
Female |
Dosed-Water |
Liver
|
Positive |
Positive |
(ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-080
|
123-91-1 |
1,4-Dioxane |
Rats |
Osborne Mendel |
Female |
Dosed-Water |
Nasal Cavity
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-080
|
123-91-1 |
1,4-Dioxane |
Rats |
Osborne Mendel |
Male |
Dosed-Water |
Nasal Cavity
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA, ADENOMA
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-143
|
2243-62-1 |
1,5-Naphthalenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(POLYP)
|
Neoplastic Lesions
|
No
|
TR-216
|
2432-99-7 |
11-Aminoundecanoic acid |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-216
|
2432-99-7 |
11-Aminoundecanoic acid |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-216
|
2432-99-7 |
11-Aminoundecanoic acid |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Hematopoietic System
|
Equivocal Evidence |
Equivocal |
LYMPHOMA 2/50 9/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-216
|
2432-99-7 |
11-Aminoundecanoic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 1/50 9/50 8/50
|
Neoplastic Lesions
|
No
|
TR-216
|
2432-99-7 |
11-Aminoundecanoic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
TRANSITIONAL CELL CARCINOMA 0/48 0/48 7/49
|
Neoplastic Lesions
|
No
|
TR-144
|
117-79-3 |
2-Aminoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-144
|
117-79-3 |
2-Aminoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
Yes
|
TR-144
|
117-79-3 |
2-Aminoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-144
|
117-79-3 |
2-Aminoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-144
|
117-79-3 |
2-Aminoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 3/50 4/50 1/49 8/49
|
May Have Been Related
|
No
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 1/50 2/49 2/49
|
May Have Been Related
|
No
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 2/50 5/50 COMBINED 0/50 1/50 2/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Some Evidence |
Equivocal Evidence |
HEPATOCELLULAR CARCINOMA 10/50 11/50 16/49 21/49
|
May Have Been Related
|
No
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Liver)
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 0/50 1/50 2/49 4/49
|
Neoplastic Lesions
|
Yes
|
TR-029
|
129-15-7 |
2-Methyl-1-nitroanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-029
|
129-15-7 |
2-Methyl-1-nitroanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-029
|
129-15-7 |
2-Methyl-1-nitroanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Positive |
Positive |
(FIBROMA)
|
Neoplastic Lesions
|
No
|
TR-029
|
129-15-7 |
2-Methyl-1-nitroanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Positive |
Positive |
(FIBROMA)
|
Neoplastic Lesions
|
No
|
TR-029
|
129-15-7 |
2-Methyl-1-nitroanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-029
|
129-15-7 |
2-Methyl-1-nitroanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
Yes
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/50 0/49 2/50 4/50
|
May Have Been Related
|
Yes
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 1/50 3/50 3/50
|
May Have Been Related
|
Yes
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 3/50 4/49 6/49 10/50
|
Neoplastic Lesions
|
Yes
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Mice |
B6C3F1/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 7/50 14/50 13/50 18/50 CARCINOMA 4/50 8/50 14/50 6/50 COMBINED 10/50 22/50 22/50 22/50
|
Neoplastic Lesions
|
No
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 0/48 0/42 5/48 CARCINOMA 1/49 1/48 1/42 7/48 COMBINED 1/49 1/48 1/42 11/48
|
Neoplastic Lesions
|
No
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Mice |
B6C3F1/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 1/50 0/50 7/50
|
Neoplastic Lesions
|
No
|
TR-516
|
693-98-1 |
2-Methylimidazole |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA OR CARCINOMA 1/48 2/46 1/43 5/50
|
Neoplastic Lesions
|
No
|
TR-169
|
5307-14-2 |
2-Nitro-p-phenylenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-169
|
5307-14-2 |
2-Nitro-p-phenylenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-169
|
5307-14-2 |
2-Nitro-p-phenylenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-169
|
5307-14-2 |
2-Nitro-p-phenylenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50
|
May Have Been Related
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 44/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 48/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Vascular System (Spleen)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50
|
Neoplastic Lesions
|
Yes
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 1/73 2/50 2/48 6/47
|
Neoplastic Lesions
|
Yes
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 8/73 9/49 8/49 17/50
|
Neoplastic Lesions
|
Yes
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Rats |
Osborne Mendel |
Female |
Gavage |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 5/75 1/49 3/50 12/49
|
Neoplastic Lesions
|
No
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Mice |
B6C3F1 |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/69 3/50 1/47 5/46
|
Neoplastic Lesions
|
No
|
TR-209
|
1746-01-6 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin |
Rats |
Osborne Mendel |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 1/69 5/48 6/50 10/50
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
ADENOMA 2/50 3/50 12/50
|
Neoplastic Lesions
|
Yes
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 3/50 8/50 8/48
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
FIBROADENOMA 15/50 21/50 18/50
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Positive |
Positive |
ADENOMA 1/47 3/47 7/49
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Pancreas Islet Cell
|
Positive |
Positive |
ADENOMA 0/50 6/49 2/47 CARCINOMA 0/50 1/49 0/47 COMBINED 0/50 7/49 2/47
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
FIBROMA 0/50 1/50 3/50 OR FIBROSARCOMA 2/50 0/50 2/50 COMBINED 2/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Male |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
FIBROMA 3/50 3/50 9/50 OR FIBROSARCOMA 0/50 3/50 3/50 COMBINED 3/50 6/50 12/50
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Mice |
B6C3F1 |
Female |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOMA 0/50 1/50 2/50 OR HEMANGIOSARCOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-162
|
95-80-7 |
2,4-Diaminotoluene (2,4-toluene diamine) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-162
|
95-80-7 |
2,4-Diaminotoluene (2,4-toluene diamine) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Positive |
Equivocal Evidence |
(LYMPHOMA)
|
May Have Been Related
|
Yes
|
TR-162
|
95-80-7 |
2,4-Diaminotoluene (2,4-toluene diamine) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-162
|
95-80-7 |
2,4-Diaminotoluene (2,4-toluene diamine) |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-162
|
95-80-7 |
2,4-Diaminotoluene (2,4-toluene diamine) |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-162
|
95-80-7 |
2,4-Diaminotoluene (2,4-toluene diamine) |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-160
|
137-17-7 |
2,4,5-Trimethylaniline |
Rats |
F344/N |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-155
|
88-06-2 |
2,4,6-Trichlorophenol |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-155
|
88-06-2 |
2,4,6-Trichlorophenol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Positive |
Positive |
(LEUKEMIA)
|
Neoplastic Lesions
|
Yes
|
TR-155
|
88-06-2 |
2,4,6-Trichlorophenol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-155
|
88-06-2 |
2,4,6-Trichlorophenol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-219
|
609-20-1 |
2,6-Dichloro-p-phenylenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-219
|
609-20-1 |
2,6-Dichloro-p-phenylenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-219
|
609-20-1 |
2,6-Dichloro-p-phenylenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
ADENOMA 4/50 4/50 9/50 OR CARCINOMA 2/50 2/50 7/50
|
Neoplastic Lesions
|
Yes
|
TR-219
|
609-20-1 |
2,6-Dichloro-p-phenylenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
ADENOMA 4/50 7/50 15/50
|
Neoplastic Lesions
|
Yes
|
TR-278
|
87-62-7 |
2,6-Xylidine |
Rats |
CD |
Female |
Dosed-Feed |
Liver
|
Positive |
Equivocal Evidence |
NEOPLASTIC NODULE 0/56 1/56 2/56 4/56
|
May Have Been Related
|
No
|
TR-278
|
87-62-7 |
2,6-Xylidine |
Rats |
CD |
Female |
Dosed-Feed |
Nasal Cavity
|
Positive |
Positive |
ADENOMA 0/56 0/56 1/56 6/56; CARCINOMA 0/56 0/56 1/56 24/56
|
Neoplastic Lesions
|
No
|
TR-278
|
87-62-7 |
2,6-Xylidine |
Rats |
CD |
Male |
Dosed-Feed |
Nasal Cavity
|
Positive |
Positive |
ADENOMA 0/56 0/56 2/56 10/56; CARCINOMA 0/56 0/56 0/56 26/56
|
Neoplastic Lesions
|
No
|
TR-278
|
87-62-7 |
2,6-Xylidine |
Rats |
CD |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Positive |
Equivocal Evidence |
FIBROMA 0/56 2/56 1/56 4/56; FIBROSARCOMA 1/56 0/56 1/56 3/56
|
May Have Been Related
|
No
|
TR-278
|
87-62-7 |
2,6-Xylidine |
Rats |
CD |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Positive |
Equivocal Evidence |
FIBROMA 0/56 1/56 2/56 4/56; FIBROSARCOMA 0/56 1/56 0/56 1/56
|
May Have Been Related
|
Yes
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Positive |
Positive |
(PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-093
|
6109-97-3 |
3-Amino-9-ethylcarbazole HCl |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-133
|
1777-84-0 |
3-Nitro-p-acetophenetide |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-133
|
1777-84-0 |
3-Nitro-p-acetophenetide |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-133
|
1777-84-0 |
3-Nitro-p-acetophenetide |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-133
|
1777-84-0 |
3-Nitro-p-acetophenetide |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/60 2/44 3/75 1/60
|
May Have Been Related
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60
|
Neoplastic Lesions
|
Yes
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60
|
Neoplastic Lesions
|
Yes
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/60 2/45 14/75 20/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 2/60 1/45 7/75 6/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75
|
Neoplastic Lesions
|
Yes
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60
|
Neoplastic Lesions
|
Yes
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/60 1/45 3/75 6/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/60 0/45 3/75 4/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Adrenal Gland Cortex
|
Clear Evidence |
Equivocal Evidence |
Adenoma 1/50 1/50 3/50 4/49
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Malignant Lymphoma: 2/50 5/50 8/50 7/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/49 3/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 1/50 0/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 1/50 1/50 1/49 3/49
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 0/50 4/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma or carcinoma 0/49 2/50 1/50 4/50 alveolar/bronchiolar adenoma or carcinoma 3/49 8/50 5/50 10/50 cystic keratinizing epithelioma 0/49 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma 5/50 16/50 12/49 6/50 alveolar/bronchiolar adenoma or carcinoma 7/50 17/50 15/49 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 6/50 26/49 39/49
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 14/50 31/50 37/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 0/50 0/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 1/50 5/50 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
Fibrosarcoma 1/50 6/50 5/50 8/50 fibrosarcoma or malignant schwannoma 2/50 8/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thoracic Cavity
|
Clear Evidence |
Equivocal Evidence |
Malignant Schwannoma: 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/50 3/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/0 0/1 0/0 1/2
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/43 0/45 1/47 0/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 32/50 46/49 49/50
|
Neoplastic Lesions
|
No
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Transitional Cell
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/48 0/47 2/50
|
May Have Been Related
|
No
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 1/48 0/47 2/50, STEP SECTIONS 1/50 0/48 3/47 5/50
|
Neoplastic Lesions
|
Yes
|
TR-423
|
119-84-6 |
3,4-Dihydrocoumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 10/51 20/50 22/50 20/52 OR CARCINOMA 3/51 2/50 4/50 6/52 COMBINED 13/51 21/50 25/50 24/52
|
Neoplastic Lesions
|
No
|
TR-085
|
5131-60-2 |
4-Chloro-m-phenylenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-085
|
5131-60-2 |
4-Chloro-m-phenylenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-085
|
5131-60-2 |
4-Chloro-m-phenylenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Positive |
Positive |
PHEOCHROMOCYTOMA
|
Neoplastic Lesions
|
Yes
|
TR-085
|
5131-60-2 |
4-Chloro-m-phenylenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-186
|
101-61-1 |
4,4'-Methylenebis(N,N-dimethyl)benzenamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Adrenal Gland Medulla
|
Positive |
Positive |
PHEOCHROMOCYTOMA 2/48 12/49 14/49
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Hematopoietic System
|
Positive |
Positive |
LYMPHOMA 13/50 28/50 29/50
|
Neoplastic Lesions
|
Yes
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Liver
|
Positive |
Positive |
ADENOMA 3/50 9/50 12/50
|
Neoplastic Lesions
|
Yes
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Liver
|
Positive |
Positive |
CARCINOMA 10/49 33/50 29/50
|
Neoplastic Lesions
|
Yes
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 1/50 12/50 25/50
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA 0/47 3/47 6/48
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/50 1/47 13/50
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/47 3/49 16/49
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA 0/47 2/47 17/48
|
Neoplastic Lesions
|
No
|
TR-248
|
13552-44-8 |
4,4'-Methylenedianiline dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA 0/49 0/47 7/48
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Positive |
Positive |
(ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Positive |
Positive |
(ADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-205
|
101-80-4 |
4,4'-Oxydianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Uterus/Cervix
|
Positive |
Positive |
ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-047
|
139-65-1 |
4,4'-Thiodianiline |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-554
|
67-47-0 |
5-(Hydroxymethyl)-2-furfural |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
Adenoma 14/50 26/49 26/50 6/50
|
Neoplastic Lesions
|
No
|
TR-187
|
95-79-4 |
5-Chloro-o-toluidine |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-187
|
95-79-4 |
5-Chloro-o-toluidine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-187
|
95-79-4 |
5-Chloro-o-toluidine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-187
|
95-79-4 |
5-Chloro-o-toluidine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-187
|
95-79-4 |
5-Chloro-o-toluidine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-187
|
95-79-4 |
5-Chloro-o-toluidine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-127
|
99-59-2 |
5-Nitro-o-anisidine |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-127
|
99-59-2 |
5-Nitro-o-anisidine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-127
|
99-59-2 |
5-Nitro-o-anisidine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-127
|
99-59-2 |
5-Nitro-o-anisidine |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Positive |
Positive |
(TRICHOEPITHELIOMA, SEBACEOUS ADENOMA, BASAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-127
|
99-59-2 |
5-Nitro-o-anisidine |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-127
|
99-59-2 |
5-Nitro-o-anisidine |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-107
|
99-55-8 |
5-Nitro-o-toluidine |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-107
|
99-55-8 |
5-Nitro-o-toluidine |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-107
|
99-55-8 |
5-Nitro-o-toluidine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-107
|
99-55-8 |
5-Nitro-o-toluidine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-107
|
99-55-8 |
5-Nitro-o-toluidine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-107
|
99-55-8 |
5-Nitro-o-toluidine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOMA OR HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Clitoral Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Ovary
|
Positive |
Positive |
(TUBULAR CELL ADENOMA OR GRANULOSA CELL TUMOR OR LUTEOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-118
|
602-87-9 |
5-Nitroacenaphthene |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-404
|
57-41-0 |
5,5-Diphenylhydantoin (phenytoin) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-404
|
57-41-0 |
5,5-Diphenylhydantoin (phenytoin) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/48 13/49 22/50, HEPATOBLASTOMA OR CARCINOMA 0/48 1/49 12/50, COMBINED 5/48 14/49 30/50
|
Neoplastic Lesions
|
No
|
TR-404
|
57-41-0 |
5,5-Diphenylhydantoin (phenytoin) |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 1/50 4/50; CARCINOMA 0/50 1/50 0/50
|
Neoplastic Lesions
|
No
|
TR-117
|
94-52-0 |
6-Nitrobenzimidazole |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-117
|
94-52-0 |
6-Nitrobenzimidazole |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-117
|
94-52-0 |
6-Nitrobenzimidazole |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-117
|
94-52-0 |
6-Nitrobenzimidazole |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
carcinoma 1/4 6/48 12/47 3/48 8/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis or Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 4/46 0/46 2/48 5/45 8/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 0/45 8/44 20/48 32/47 31/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 2/48 1/48 0/48 2/48 4/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 1/48 2/48 3/48 4/48 6/48
|
Neoplastic Lesions
|
Yes
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 1/48 3/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 16/48 18/48 24/46 22/47 31/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Pancreas Islet Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/48 2/48 1/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48
|
Neoplastic Lesions
|
No
|
TR-021
|
309-00-2 |
Aldrin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-021
|
309-00-2 |
Aldrin |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Adrenal Gland Cortex
|
Equivocal Evidence |
Equivocal |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-021
|
309-00-2 |
Aldrin |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-021
|
309-00-2 |
Aldrin |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-021
|
309-00-2 |
Aldrin |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 26/50 32/50 29/50 38/50
|
May Have Been Related
|
No
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA (STANDARD EVALUATION) 0/50 0/50 1/50 0/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 2/50 5/50 ADENOMA OR CARCINOMA (STANDARD EVALUATION) 0/50 0/50 2/50 2/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 28/50 36/50 33/50 37/50
|
May Have Been Related
|
Yes
|
TR-543
|
98-83-9 |
alpha-Methylstyrene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 20/50 21/50 23/50 CARCINOMA 3/50 9/50 6/50 18/50 ADENOMA OR CARCINOMA 13/50 26/50 24/50 33/50
|
Neoplastic Lesions
|
No
|
TR-560
|
63-05-8 |
Androstenedione |
Rats |
F344/N |
Female |
Gavage |
All Organs
|
Equivocal Evidence |
Equivocal Evidence |
Mononuclear cell leukemia 5/50 11/50 18/50 15/50 (choose all organs until programmer intervention)
|
May Have Been Related
|
Yes
|
TR-560
|
63-05-8 |
Androstenedione |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 14/50 16/50 18/50 28/50 carcinoma 5/50 13/50 15/50 15/50 adenoma or carcinoma 17/50 23/50 27/50 32/50
|
Neoplastic Lesions
|
Yes
|
TR-560
|
63-05-8 |
Androstenedione |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Hepatocellular adenoma, multiple 16/50 27/50 23/50 34/50 hepatocellular adenoma (includes multiples) 32/50 38/50 29/50 43/50 hepatocellular carcinoma multiple 7/50 12/50 10/50 17/50 hepatocellular adenoma or hepatocellular carcinoma (combined includes multiples) 41/50 47/50 42/50 48/50 hepatoblastoma 3/50 8/50 7/50 8/50 hepatocellular adenoma, carcinoma, or hepatoblastoma (combined) 41/50 47/50 43/50 48/50
|
Neoplastic Lesions
|
No
|
TR-560
|
63-05-8 |
Androstenedione |
Rats |
F344/N |
Male |
Gavage |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
Alveolar/bronchiolar adenoma 0/50 0/50 5/50 2/50 alveolar/bronchiolar adenoma or carcinoma (combined) 0/50 0/50 5/50 3/50
|
May Have Been Related
|
No
|
TR-560
|
63-05-8 |
Androstenedione |
Mice |
B6C3F1/N |
Female |
Gavage |
Pancreas Islet Cell
|
Clear Evidence |
Clear Evidence |
Adenoma 0/49 2/50 4/49 4/48
|
Neoplastic Lesions
|
No
|
TR-560
|
63-05-8 |
Androstenedione |
Mice |
B6C3F1/N |
Male |
Gavage |
Pancreas Islet Cell
|
Clear Evidence |
Clear Evidence |
Adenoma (includes multiples) 2/50 2/50 2/50 5/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Some Evidence |
Some Evidence |
PAPILLOMA 0/50 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 9/50 7/50 12/49; ADENOMA OR CARCINOMA 0/50 6/50 9/50 8/50 14/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 3/50 9/50 5/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 1/50 3/50 4/50 5/50 3/50
|
May Have Been Related
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/49 28/50 27/50 40/49 OR CARCINOMA 2/49 3/50 8/50 8/49 COMBINED 6/49 30/50 30/50 41/49
|
Neoplastic Lesions
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 21/50 32/50 38/50 41/49 OR CARCINOMA 8/50 13/50 17/50 21/49 OR HEPATOBLASTOMA 1/50 6/50 11/50 37/49 COMBINED 26/50 35/50 43/50 48/49
|
Neoplastic Lesions
|
Yes
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 6/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/45 1/48 2/48 2/48 OR CARCINOMA 0/45 0/48 0/48 2/48 COMBINED 1/45 1/48 2/48 4/48
|
May Have Been Related
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 2/49 2/46
|
May Have Been Related
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL EPITHELIAL PAPILLOMA OR CARCINOMA 0/49 0/49 0/49 1/50 2/49
|
Neoplastic Lesions
|
No
|
TR-494
|
84-65-1 |
Anthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Some Evidence |
Some Evidence |
TRANSITIONAL EPITHELIAL PAPILLOMA 0/50 1/50 3/50 7/50 3/49
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 COMBINED 2/50 9/50 5/50
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/49 7/39 10/48 OR SQUAMOUS CELL CARCINOMA 0/49 4/39 3/48 COMBINED 2/49 11/39 13/48
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOCARCINOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 22/48 21/47; HEPATOBLASTOMA 0/50 1/48 2/47; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 3/50 3/48 1/47 COMBINED 4/50 25/48 22/47
|
Neoplastic Lesions
|
Yes
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/49 24/39 34/48; HEPATOBLASTOMA 0/49 3/39 18/48; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 9/49 8/39 9/48 COMBINED 12/49 31/39 40/48
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 5/48 13/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/48 3/47 COMBINED 2/50 9/48 14/47
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 7/39 15/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/49 3/39 5/48 COMBINED 10/49 9/39 19/48
|
Neoplastic Lesions
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 27/50 41/50 39/50 24/50
|
May Have Been Related
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Equivocal Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 19/50 25/50 30/50 29/50; HISTIOCYTIC SARCOMA 0/50 0/50 1/50 2/50
|
Neoplastic Lesions
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Some Evidence |
Some Evidence |
HISTIOCYTIC SARCOMA: 0/50 0/50 5/50 3/50
|
Neoplastic Lesions
|
No
|
TR-533
|
119-61-9 |
Benzophenone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA (STANDARD EVALUATION) 1/50 1/50 2/50 4/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 2/50 2/50 7/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-533
|
119-61-9 |
Benzophenone |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA 5/50 4/50 10/50 8/50
|
May Have Been Related
|
Yes
|
TR-533
|
119-61-9 |
Benzophenone |
Mice |
B6C3F1/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 11/50 15/50 23/50 23/50 ADENOMA, CARCINOMA, OR HEPATOBLASTOMA 18/50 20/50 25/50 29/50
|
Neoplastic Lesions
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/48
|
Neoplastic Lesions
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 3/49 3/48 9/49 OR SQUAMOUS CELL CARCINOMA 1/49 1/48 2/49 COMBINED 4/49 4/48 11/49
|
Neoplastic Lesions
|
Yes
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 5/49 13/50
|
Neoplastic Lesions
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 22/50 27/50 37/49
|
Neoplastic Lesions
|
No
|
TR-557
|
123-35-3 |
beta-Myrcene |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
Adenoma (standard evaluation) 0/50 1/50 0/50 2/50 extended evaluation 0/50 1/50 1/50 2/50 standard and extended evaluations 0/50 2/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-557
|
123-35-3 |
beta-Myrcene |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
Adenoma (standard evaluation) 0/50 4/50 8/50 (standard and extended evaluations) 0/50 12/50 13/50 adenoma or carcinoma (standard evaluation) 0/50 7/50 9/50 (standard and extended evaluations) 0/50 14/50 13/50
|
Neoplastic Lesions
|
No
|
TR-557
|
123-35-3 |
beta-Myrcene |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
Adenoma 6/50 13/50 6/50 carcinoma 1/50 7/50 2/50 adenoma or carcinoma 7/50 18/50 8/50
|
May Have Been Related
|
Yes
|
TR-557
|
123-35-3 |
beta-Myrcene |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 26/50 41/50 43/50 carcinoma 14/50 20/50 28/50 adenoma or carcinoma 33/50 44/50 48/50 hepatoblastoma 4/50 6/50 11/50 adenoma, carcinoma, or hepatoblastoma 34/50 45/50 48/50
|
Neoplastic Lesions
|
No
|
TR-580
|
108-99-6 |
beta-Picoline |
Rats |
F344/N |
Male |
Dosed-Water |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-580
|
108-99-6 |
beta-Picoline |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 11/49 20/50 26/50 23/50 hepatoblastoma 1/49 3/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-580
|
108-99-6 |
beta-Picoline |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
alveolar/bronchiolar adenoma 6/50 11/50 16/50 8/50 alveolar/bronchiolar adenoma or carcinoma 14/50 19/50 21/50 15/50
|
May Have Been Related
|
No
|
TR-580
|
108-99-6 |
beta-Picoline |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 5/50 6/50 4/49 11/50 carcinoma 7/50 8/50 10/49 13/50 alveolar/bronchiolar adenoma or carcinoma 11/50 13/50 13/49 21/50
|
Neoplastic Lesions
|
No
|
TR-580
|
108-99-6 |
beta-Picoline |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Some Evidence |
Some Evidence |
alveolar/bronchiolar adenoma 0/50 3/50 2/50 5/50 alveolar/bronchiolar adenoma or carcinoma 0/50 4/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/49 1/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/49 1/49 COMBINED 0/50 0/49 2/49
|
May Have Been Related
|
Yes
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 5/50 13/50 17/50
|
Neoplastic Lesions
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 4/50 8/50
|
Neoplastic Lesions
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 13/50 11/50
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Female |
Gavage |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/46 0/50 7/47; ADENOCARCINOMA 0/46 0/50 6/47
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Male |
Gavage |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 3/50 33/50; ADENOCARCINOMA 0/50 11/50 38/50
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 2/50 6/50; ADENOCARCINOMA 0/49 0/50 4/50; COMBINED 1/49 2/50 9/50
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 6/50; ADENOCARCINOMA 0/50 0/50 9/50; COMBINED 0/50 1/50 15/50
|
Neoplastic Lesions
|
No
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 3/50; ADENOCARCINOMA 0/50 0/50 10/50; COMBINED 0/50, 1/50, 13/50
|
Neoplastic Lesions
|
Yes
|
TR-321
|
75-27-4 |
Bromodichloromethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 13/48 23/50; CARCINOMA 2/50 5/48 10/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 1/50 3/35 5/64 1/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 16/50 11/35 24/63 19/49 OR MALIGNANT PHEOCHROMOCYTOMA 2/50 0/35 3/63 2/49 COMBINED 17/50 11/35 27/63 21/49
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 0/65 3/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 0/35 1/65 2/50
|
Neoplastic Lesions
|
Yes
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/35 15/64 6/50, CARCINOMA 0/50 0/35 6/64 3/50, COMBINED 0/50 0/35 19/64 8/50
|
Neoplastic Lesions
|
Yes
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 2/50 1/35 10/65 15/50, CARCINOMA 0/50 1/35 6/65 7/50, COMBINED 2/50 2/35 15/65 20/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 2/35 1/65 3/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 2/50 2/35 2/65 3/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/35 8/65 4/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 1/50 2/35 9/65 4/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 3/35 6/65 3/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/35 1/65 2/50
|
May Have Been Related
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/35 6/65 4/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 3/65 2/50, COMBINED 0/50 3/35 9/65 6/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 2/65 6/50, CARCINOMA 0/50 3/35 17/65 13/50, COMBINED 0/50 3/35 18/65 19/50
|
Neoplastic Lesions
|
No
|
TR-405
|
6459-94-5 |
C.I. Acid Red 114 |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 1/65 1/50, CARCINOMA 0/50 0/35 7/65 6/50, COMBINED 0/50 0/35 8/65 7/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 1/48 7/47 7/45 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 1/45 COMBINED 1/48 8/47 8/45
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
LYMPHOMA 17/50 24/50 25/50
|
May Have Been Related
|
Yes
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 3/49 19/50 37/49
|
Neoplastic Lesions
|
Yes
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 10/50 20/50 27/50
|
Neoplastic Lesions
|
Yes
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 2/50 8/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 3/50 1/50, FIBROADENOMA 22/50 31/50 29/50, OR ADENOCARCINOMA 2/50 2/50 5/50 COMBINED 23/50 32/50 32/50
|
May Have Been Related
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
TRICHOEPITHELIOMA 0/50 0/50 7/50; SEBACEOUS ADENOMA 0/50 0/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 1/50 10/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 0/50 15/50 10/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/50 20/50 16/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/47 0/48 4/50 OR CARCINOMA 0/47 2/48 2/50 COMBINED 0/47 2/48 6/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 0/46 9/44 OR CARCINOMA 0/49 5/46 18/44
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 2/50 7/50
|
Neoplastic Lesions
|
No
|
TR-285
|
569-61-9 |
C.I. Basic Red 9 Monohydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 1/50 13/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 1/35 1/65 2/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/35 3/65 1/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 6/65 8/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/35 1/65 3/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 0/65 2/50
|
Neoplastic Lesions
|
Yes
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50
|
Neoplastic Lesions
|
Yes
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 0/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 1/50 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 2/50 1/50 1/50 OR CARCINOMA 0/50 1/50 0/50 0/50 COMBINED 0/50 3/50 1/50 1/50
|
May Have Been Related
|
Yes
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/49 12/50 17/49 41/49; CARCINOMA 5/49 5/50 6/49 12/49
|
Neoplastic Lesions
|
Yes
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 16/50 19/50 17/50 40/50; CARCINOMA 7/50 3/50 8/50 17/50
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 0/50 5/51; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 1/51; BASOSQUAMOUS TUMOR BENIGN 0/50 0/50 0/50 1/51
|
Neoplastic Lesions
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/49 1/50 0/50; FIBROSARCOMA 0/49 1/50 0/50; SARCOMA 0/49 0/50 1/50
|
May Have Been Related
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Glandular Stomach
|
Positive |
Equivocal Evidence |
ADENOMA 0/49 1/50 0/50; ADENOCARCINOMA 0/49 1/501/50; SARCOMA 0/49 0/50 1/50
|
May Have Been Related
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Positive |
Equivocal Evidence |
LYMPHOMA 10/50 16/50 19/50
|
May Have Been Related
|
Yes
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
ADENOMA 0/50 6/50 12/50
|
Neoplastic Lesions
|
Yes
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 1/49 15/50 10/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 24/50 32/50 37/50 36/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 0/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 1/50 10/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 2/50 6/50
|
May Have Been Related
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/49 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-407
|
2425-85-6 |
C.I. Pigment Red 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 2/50 3/50
|
May Have Been Related
|
No
|
TR-226
|
842-07-9 |
C.I. Solvent Yellow 14 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-226
|
842-07-9 |
C.I. Solvent Yellow 14 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-226
|
842-07-9 |
C.I. Solvent Yellow 14 |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 2/50 3/49 10/48
|
Neoplastic Lesions
|
Yes
|
TR-226
|
842-07-9 |
C.I. Solvent Yellow 14 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 5/50 10/50 30/50
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
benign, malignant, or complex pheochromocytoma (1/86, 9/89, 5/87, 4/88)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
glioma malignant (0/90, 3/90, 0/90, 0/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Clear Evidence |
glioma malignant (0/90, 0/90, 0/90, 3/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Heart
|
Equivocal Evidence |
Equivocal Evidence |
schwannoma malignant (0/90, 2/90, 0/90, 2/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Heart
|
Clear Evidence |
Clear Evidence |
schwannoma malignant (0/90, 2/90, 3/90, 6/90)
|
Neoplastic Lesions
|
Yes
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Liver
|
Clear Evidence |
Equivocal Evidence |
hepatocellular adenoma or carcinoma (combined) (0/90, 2/90, 4/89, 1/88)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pituitary Gland
|
Clear Evidence |
Equivocal Evidence |
pars distalis, adenoma (17/89, 25/90, 34/90, 13/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
benign, malignant, or complex pheochromocytoma (11/88, 24/90, 28/89, 14/87)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Equivocal Evidence |
meninges, granular cell tumor benign or malignant (1/90, 3/90, 4/90, 3/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Clear Evidence |
glioma malignant (0/90, 3/90, 3/90, 2/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Heart
|
Equivocal Evidence |
Equivocal Evidence |
schwannoma malignant (0/90, 0/90, 2/90, 0/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Heart
|
Clear Evidence |
Clear Evidence |
schwannoma malignant (0/90, 2/90, 1/90, 5/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pancreas Islet Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma (13/90, 27/89, 19/86, 16/85)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pituitary Gland
|
Clear Evidence |
Equivocal Evidence |
pars distalis, adenoma (17/89, 28/90, 26/90, 26/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Prostate Gland
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma (2/90, 2/90, 7/90, 3/90)
|
May Have Been Related
|
Yes
|
TR-503
|
302-17-0 |
Chloral hydrate |
Mice |
MV |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
CARCINOMA 2/48 5/58 4/48 8/48 (DIETARY-CONTROLLED GROUPS)
|
Neoplastic Lesions
|
Yes
|
TR-503
|
302-17-0 |
Chloral hydrate |
Mice |
MV |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADEMONA OR CARCINOMA 16/48 25/48 23/47 22/48 (AD LIBITUM-FED GROUPS)
|
Neoplastic Lesions
|
No
|
TR-025
|
133-90-4 |
Chloramben |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-025
|
133-90-4 |
Chloramben |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-025
|
133-90-4 |
Chloramben |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-025
|
133-90-4 |
Chloramben |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-008
|
57-74-9 |
Chlordane (analytical grade) |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-008
|
57-74-9 |
Chlordane (analytical grade) |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-008
|
57-74-9 |
Chlordane (analytical grade) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-008
|
57-74-9 |
Chlordane (analytical grade) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-000 (143-50-0)
|
143-50-0 |
Chlordecone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA; HYPERPLASIA
|
Neoplastic Lesions
|
Yes
|
TR-000 (143-50-0)
|
143-50-0 |
Chlordecone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA; HYPERPLASIA
|
Neoplastic Lesions
|
Yes
|
TR-000 (143-50-0)
|
143-50-0 |
Chlordecone |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA; HYPERPLASIA
|
Neoplastic Lesions
|
Yes
|
TR-000 (143-50-0)
|
143-50-0 |
Chlordecone |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA; HYPERPLASIA
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-304
|
115-28-6 |
Chlorendic acid |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 9/49 10/50; CARCINOMA 9/50 17/49 20/50
|
Neoplastic Lesions
|
Yes
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/50 3/49 11/50; CARCINOMA 0/50 3/49 5/50
|
Neoplastic Lesions
|
Yes
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 2/50 21/50 23/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 3/50 5/50
|
May Have Been Related
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Preputial Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 1/50 8/50 4/50
|
May Have Been Related
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
LEUKEMIA 7/50 12/50 14/50
|
May Have Been Related
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/49 ADENOCARCINOMA 0/50 2/50 0/49 COMBINED 0/50 9/50 3/49
|
Neoplastic Lesions
|
Yes
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 18/50 22/50 OR CARCINOMA 3/50 4/50 9/50 COMBINED 3/50 22/50 28/50
|
Neoplastic Lesions
|
Yes
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/50 20/50 29/50 OR CARCINOMA 11/50 15/50 17/50 COMBINED 2/50 34/50 38/50
|
Neoplastic Lesions
|
Yes
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 4/50 7/50; CARCINOMA 0/50 1/50 1/50
|
Neoplastic Lesions
|
Yes
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 10/50 16/48; CARCINOMA 0/50 3/50 2/48
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Mice |
B6C3F1 |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 12/49 18/49 OR CARCINOMA 0/50 0/49 2/49 COMBINED 8/50 12/49 15/49
|
Neoplastic Lesions
|
No
|
TR-308
|
108171-26-2 |
Chlorinated paraffins: C12, 60% chlorine |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 6/50 3/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 6/50 6/50
|
Neoplastic Lesions
|
No
|
TR-075
|
510-15-6 |
Chlorobenzilate |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Adrenal Gland Cortex
|
Equivocal Evidence |
Equivocal |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-075
|
510-15-6 |
Chlorobenzilate |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Adrenal Gland Cortex
|
Equivocal Evidence |
Equivocal |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-075
|
510-15-6 |
Chlorobenzilate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-075
|
510-15-6 |
Chlorobenzilate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-282
|
124-48-1 |
Chlorodibromomethane |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-282
|
124-48-1 |
Chlorodibromomethane |
Rats |
F344/N |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-282
|
124-48-1 |
Chlorodibromomethane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 14/50 10/50 OR CARCINOMA 10/50 19/50 COMBINED 23/50 27/50
|
Neoplastic Lesions
|
Yes
|
TR-282
|
124-48-1 |
Chlorodibromomethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 2/50 4/49 11/50 OR CARCINOMA 4/50 6/49 8/50 COMBINED 6/50 10/49 19/50
|
Neoplastic Lesions
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Rats |
F344/N |
Female |
Inhalation |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-346
|
75-00-3 |
Chloroethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 1/48 OR CARCINOMA 3/49 7/48 COMBINED 3/49 8/48
|
May Have Been Related
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Rats |
F344/N |
Male |
Inhalation |
Skin
|
Equivocal Evidence |
Equivocal Evidence |
TRICHOEPITHELIOMA 0/49 1/46, SEBACEOUS GLAND ADENOMA 0/49 1/46, OR BASAL CELL CARCINOMA 0/49 3/46 COMBINED 0/49 5/46
|
Neoplastic Lesions
|
No
|
TR-346
|
75-00-3 |
Chloroethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ENDOMETRIAL CARCINOMA 0/49 43/50
|
Neoplastic Lesions
|
No
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Rats |
Osborne Mendel |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Rats |
Osborne Mendel |
Male |
Gavage |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA COMBINED
|
Neoplastic Lesions
|
Yes
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-000 (67-66-3)
|
67-66-3 |
Chloroform |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous Cell Papilloma 0/50 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 3/50 4/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 24/49 32/50 36/50 36/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 4/50 8/50 3/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 11/50 11/50 18/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Rats |
F344/N |
Female |
Topical Application |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
adenoma or carcinoma (standard evaluation 0/50, 2/50, 0/50; standard and extended evaluations combined 0/50, 4/50, 1/50)
|
May Have Been Related
|
No
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Mice |
B6C3F1 |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/50, 1/50, 7/50; renal tubule adenoma or carcinoma 1/50, 1/50, 9/50
|
Neoplastic Lesions
|
Yes
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Mice |
B6C3F1 |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 32/50, 44/50, 43/50; hepatocellular carcinoma 3/50, 21/50, 32/50; hepatocellular adenoma, carcinoma, or hepatoblastoma 33/50, 46/50, 48/50
|
Neoplastic Lesions
|
Yes
|
TR-479
|
68603-42-9 |
Coconut oil acid diethanolamine condensate |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 22/50, 35/50, 45/50; hepatoblastoma 1/50, 1/50, 10/50; hepatocellular adenoma, carcinoma, or hepatoblastoma 29/50, 39/50, 49/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/52 5/50 2/51 2/51
|
May Have Been Related
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 2/50 0/51
|
May Have Been Related
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/50 0/50 2/49, STEP SECTIONS 0/49 0/50 1/50 1/49
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/49 2/50 2/51 1/50, STEP SECTIONS 0/49 4/50 5/51 4/50
|
Neoplastic Lesions
|
Yes
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 26/49 29/51 12/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/51 5/49 7/49 20/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 0/49 0/49 7/51 COMBINED 2/51 5/49 7/49 27/51
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 14/50 8/50 14/50 24/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 1/50 2/50 1/51 COMBINED 14/50 9/50 15/50 25/51
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
renal tubule, adenoma or carcinoma (2/50, 5/50, 8/50, 7/50)
|
Neoplastic Lesions
|
Yes
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma (18/50, 23/50, 27/50, 29/50); adenoma or carcinoma (25/50, 26/50, 29/50, 36/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (1/50, 26/50, 36/50, 38/50); alveolar/bronchiolar carcinoma (3/50, 16/50, 20/50, 34/50); alveolar/bronchiolar adenoma or carcinoma (4/50, 31/50, 42/50, 46/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma (13/50, 31/50, 31/50, 29/50); alveolar/bronchiolar carcinoma (9/50, 19/50, 32/50, 33/50); alveolar/bronchiolar adenoma or carcinoma (19/50, 38/50, 42/50, 43/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
respiratory epithelium, adenoma (0/50, 7/50, 18/49, 10/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Female |
Inhalation |
Nasal Cavity
|
Some Evidence |
Some Evidence |
respiratory epithelium, adenoma (0/50, 5/48, 4/50, 3/50)
|
Neoplastic Lesions
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Spleen
|
Clear Evidence |
Equivocal Evidence |
hemangioscaroma
|
May Have Been Related
|
No
|
TR-542
|
98-82-8 |
Cumene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Equivocal Evidence |
interstitial cell adenoma
|
May Have Been Related
|
No
|
TR-542
|
98-82-8 |
Cumene |
Mice |
B6C3F1/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma
|
May Have Been Related
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOMA OR HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-225
|
5160-02-1 |
D&C Red No. 9 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-225
|
5160-02-1 |
D&C Red No. 9 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-225
|
5160-02-1 |
D&C Red No. 9 |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
NEOPLASTIC NODULE 1/50 1/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-225
|
5160-02-1 |
D&C Red No. 9 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 0/50 6/50 7/49
|
Neoplastic Lesions
|
No
|
TR-225
|
5160-02-1 |
D&C Red No. 9 |
Rats |
F344/N |
Male |
Dosed-Feed |
Spleen
|
Positive |
Positive |
SARCOMA 0/50 0/50 26/48
|
Neoplastic Lesions
|
No
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 0/51 0/51 2/54 OR CARCINOMA 0/50 0/51 1/51 0/54 COMBINED 0/50 0/51 1/51 2/54; (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/51 4/51 4/54 OR CARCINOMA 0/50 0/51 1/51 0/54 COMBINED 0/50 2/51 5/51 4/54
|
Neoplastic Lesions
|
Yes
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 2/51 5/50 4/51 OR CARCINOMA 0/50 0/51 0/50 1/51 COMBINED 0/50 2/51 5/50 5/51
|
Neoplastic Lesions
|
Yes
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 2/51 1/51 7/54
|
Neoplastic Lesions
|
No
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 0/50 0/51 0/50 1/51
|
May Have Been Related
|
No
|
TR-463
|
8003-22-3 |
D&C Yellow No. 11 |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 1/51 2/51 4/54 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/51 1/54 COMBINED 1/50 2/51 3/51 5/54
|
Neoplastic Lesions
|
No
|
TR-309
|
1163-19-5 |
Decabromodiphenyl Oxide |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-309
|
1163-19-5 |
Decabromodiphenyl Oxide |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 4/50 12/50 12/50 OR CARCINOMA 5/50 14/50 8/50 COMBINED 8/50 22/50 18/50
|
Neoplastic Lesions
|
Yes
|
TR-309
|
1163-19-5 |
Decabromodiphenyl Oxide |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
NEOPLASTIC NODULE 1/50 3/49 9/50
|
Neoplastic Lesions
|
Yes
|
TR-309
|
1163-19-5 |
Decabromodiphenyl Oxide |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
NEOPLASTIC NODULE 1/50 7/50 15/49
|
Neoplastic Lesions
|
No
|
TR-309
|
1163-19-5 |
Decabromodiphenyl Oxide |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 3/50 3/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 0/50 4/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (1/49, 0/50, 5/50, 9/50, 5/48); hepatocellular carcinoma (0/49, 0/50, 0/50, 0/50, 8/48); hepatocellular adenoma or carcinoma (combined) (1/49, 0/50, 5/50, 9/50, 13/48)
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (0/50, 0/50, 1/50, 1/50, 13/49); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 2/49); hepatocellular adenoma or carcinoma (combined) (0/50, 0/50, 1/50, 1/50, 14/49)
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (0/50, 1/49, 0/50, 3/50, 8/49); hepatocellular carcinoma (1/50, 0/49, 0/50, 0/50, 3/49); hepatocellular adenoma or carcinoma (combined) (1/50, 1/49, 0/50, 3/50, 11/49)
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (0/50, 2/50, 0/50, 1/50, 6/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 6/50); hepatocellular adenoma or carcinoma (combined) (0/50, 2/50, 0/50, 1/50, 12/50)
|
Neoplastic Lesions
|
Yes
|
TR-217
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA 0/50 7/50 17/50
|
Neoplastic Lesions
|
Yes
|
TR-217
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA 9/50 14/48 19/50
|
Neoplastic Lesions
|
Yes
|
TR-217
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA 0/50 2/49 8/50
|
Neoplastic Lesions
|
Yes
|
TR-217
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 2/50 5/49 7/49 OR CARCINOMA 1/50 1/49 5/49 COMBINED 3/50 6/49 12/49
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma or carcinoma (combined) (0/50, 0/50, 0/50, 1/50, 2/47)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma or carcinoma (combined) (0/49, 0/50, 0/50, 2/50, 1/48)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma (1/49, 4/50, 5/50, 23/50, 30/50); acinar carcinoma (0/49, 1/50, 0/50, 1/50, 5/50); acinar adenoma or carcinoma (combined) (1/49, 5/50, 5/50, 23/50, 33/50)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma (10/50, 7/49, 8/50, 36/50, 22/49); acinar carcinoma (0/50, 0/49, 0/50, 3/50, 1/49); acinar adenoma or carcinoma (combined) (10/50, 7/49, 8/50, 38/50, 22/49)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Testis
|
Clear Evidence |
Equivocal Evidence |
interstitial cell, adenoma (7/50, 3/50, 3/50, 6/50, 15/50)
|
May Have Been Related
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Clear Evidence |
Equivocal Evidence |
adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (3/50, 1/50, 1/50, 3/50, 7/50)
|
May Have Been Related
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Clear Evidence |
Clear Evidence |
adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (2/50, 4/50, 1/50, 6/50, 13/50)
|
Neoplastic Lesions
|
No
|
TR-212
|
103-23-1 |
Di(2-ethylhexyl)adipate |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-212
|
103-23-1 |
Di(2-ethylhexyl)adipate |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-212
|
103-23-1 |
Di(2-ethylhexyl)adipate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA 1/50 14/50 12/49
|
Neoplastic Lesions
|
Yes
|
TR-212
|
103-23-1 |
Di(2-ethylhexyl)adipate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
ADENOMA 6/50 8/49 15/49
|
Neoplastic Lesions
|
No
|
TR-131
|
50-29-3 |
Dichlorodiphenyltrichloroethane (DDT) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-131
|
50-29-3 |
Dichlorodiphenyltrichloroethane (DDT) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-131
|
50-29-3 |
Dichlorodiphenyltrichloroethane (DDT) |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-131
|
50-29-3 |
Dichlorodiphenyltrichloroethane (DDT) |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-090
|
115-32-2 |
Dicofol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-090
|
115-32-2 |
Dicofol |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-090
|
115-32-2 |
Dicofol |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-090
|
115-32-2 |
Dicofol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-021
|
60-57-1 |
Dieldrin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-021
|
60-57-1 |
Dieldrin |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-021
|
60-57-1 |
Dieldrin |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-021
|
60-57-1 |
Dieldrin |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-478
|
111-42-2 |
Diethanolamine |
Mice |
B6C3F1 |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 4/50 6/50 6/50 COMBINED 3/50 5/50 6/50 8/50; (SINGLE AND STEP SECTIONS) ADENOMA 1/50 6/50 8/50 7/50 COMBINED 3/50 7/50 8/50 9/50
|
Neoplastic Lesions
|
Yes
|
TR-478
|
111-42-2 |
Diethanolamine |
Mice |
B6C3F1 |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 32/50 50/50 48/50 48/50 OR CARCINOMA 5/50 19/50 38/50 42/50
|
Neoplastic Lesions
|
Yes
|
TR-478
|
111-42-2 |
Diethanolamine |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 31/50 42/50 49/50 45/50, CARCINOMA 12/50 17/50 33/50 34/50 OR HEPATOBLASTOMA 0/50 2/50 8/50 5/50
|
Neoplastic Lesions
|
No
|
TR-512
|
37319-17-8 |
Elmiron (sodium pentosanpolysulfate) |
Mice |
B6C3F1 |
Female |
Gavage |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MALIGNANT LYMPHOMA (ALL ORGANS) 7/50 8/50 6/50 16/50
|
May Have Been Related
|
Yes
|
TR-512
|
37319-17-8 |
Elmiron (sodium pentosanpolysulfate) |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 23/50 23/50 26/50 31/50
|
May Have Been Related
|
Yes
|
TR-512
|
37319-17-8 |
Elmiron (sodium pentosanpolysulfate) |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 1/50 1/49 1/50 4/49; ADENOMA 7/50 5/49 4/50 15/49; HEPATOCELLULAR ADENOMA OR CARCINOMA 10/50 8/49 9/50 18/49
|
Neoplastic Lesions
|
Yes
|
TR-512
|
37319-17-8 |
Elmiron (sodium pentosanpolysulfate) |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 2/50 0/50 4/50 9/50
|
Neoplastic Lesions
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Female |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Male |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 3/50 2/50 4/50 OR CARCINOMA 0/50 0/50 1/50 3/50 COMBINED 0/50 3/50 3/50 7/50; (SINGLE AND STEP SECTIONS) ADENOMA 3/50 5/50 7/50 20/50 OR CARCINOMA 0/50 0/50 1/50 3/50 COMBINED 3/50 5/50 8/50 21/50
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 0/50 0/50 1/49 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 0/50 1/50 8/49
|
Neoplastic Lesions
|
Yes
|
TR-466
|
100-41-4 |
Ethylbenzene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 6/50 9/50 12/50 16/50 OR CARCINOMA 7/50 4/50 3/50 12/50 COMBINED 13/50 12/50 15/50 25/50
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 9/50 10/50 16/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 1/50 5/50 3/50 COMBINED 7/50 10/50 15/50 19/50
|
Neoplastic Lesions
|
No
|
TR-466
|
100-41-4 |
Ethylbenzene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Clear Evidence |
ADENOMA 36/50 33/50 40/50 44/50
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 2/50 33/50; CARCINOMA 2/50 29/50 47/50
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/49 16/50 9/50; CARCINOMA 13/49 19/50 45/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/47 19/49 26/49; CARCINOMA 1/47 0/49 0/49
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/44 0/42 8/41
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 35/50 CARCINOMA 0/50 0/50 8/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/49 26/50 CARCINOMA 1/50 0/49 5/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 6/44 28/49 CARCINOMA 2/50 1/44 8/49
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 9/46 23/50 CARCINOMA 1/49 3/46 26/50
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Guppy (Poecilia reticulata) |
Female |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOMA 0/64 3/64 4/47 2/33 CHOLANGIOCARCINOMA 0/64 0/64 0/47 6/33 ADENOMA OR CARCINOMA 5/64 4/64 4/47 8/33
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Guppy (Poecilia reticulata) |
Female |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOMA 2/31 2/31 0/31 2/27 CHOLANGIOCARCINOMA 0/31 0/31 0/31 5/27 ADENOMA OR CARCINOMA 2/31 1/31 2/31 3/27
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Medaka (Oryzias latipes) |
Female |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOCARCINOMA 1/57 15/44 31/49 21/31 ADENOMA 4/57 2/44 2/49 1/31 CARCINOMA 0/57 2/44 1/49 4/31 ADENOMA OR CARCINOMA 4/57 4/44 2/49 5/31 HEPATOCHOLANGIOCARCINOMA 0/57 0/44 0/49 1/31
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Medaka (Oryzias latipes) |
Female |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOCARCINOMA 0/95 29/93 53/94 41/67 ADENOMA 1/95 1/93 5/94 8/67 CARCINOMA 1/95 1/93 2/94 5/67 ADENOMA OR CARCINOMA 2/95 2/93 7/94 13/67 HEPATOCHOLANGIOCARCINOMA 0/95 0/93 4/94 7/67
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Medaka (Oryzias latipes) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOMA 0/95 6/94 2/65 1/78 CHOLANGIOCARCINOMA 0/95 32/94 43/65 45/78 ADENOMA OR CARCINOMA 0/95 2/94 1/65 6/78 HEPATOCHOLANGIOCARCINOMA 0/95 0/94 2/65 6/78
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Medaka (Oryzias latipes) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOMA 0/42 0/47 3/33 1/46 CHOLANGIOCARCINOMA 0/42 19/47 16/33 26/46 ADENOMA 0/42 1/47 0/33 0/46 ADENOMA OR CARCINOMA 0/42 2/47 0/33 1/46
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Guppy (Poecilia reticulata) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOCARCINOMA 0/32 0/19 0/26 1/19 ADENOMA 3/32 4/19 5/26 7/19 CARCINOMA 0/32 0/19 1/26 4/19 ADENOMA OR CARCINOMA COMBINED 3/32 4/19 5/26 10/19
|
Neoplastic Lesions
|
Yes
|
TR-528
|
96-18-4 |
Fish project 1 (1,2,3-Trichloropropane) |
Fish |
Guppy (Poecilia reticulata) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
CHOLANGIOCARCINOMA 0/61 0/47 0/67 3/27 ADENOMA 3/61 8/47 17/67 9/27 CARCINOMA 0/61 1/47 0/67 7/27 ADENOMA OR CARCINOMA COMBINED 3/61 9/47 17/67 15/27
|
Neoplastic Lesions
|
No
|
TR-528
|
3296-90-0 |
Fish project 1 (2,2-bis(Bromomethyl)-1,3-propanediol) |
Fish |
Guppy (Poecilia reticulata) |
Female |
Aquatic |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-528
|
3296-90-0 |
Fish project 1 (2,2-bis(Bromomethyl)-1,3-propanediol) |
Fish |
Medaka (Oryzias latipes) |
Female |
Aquatic |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-528
|
3296-90-0 |
Fish project 1 (2,2-bis(Bromomethyl)-1,3-propanediol) |
Fish |
Guppy (Poecilia reticulata) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
ADENOMA 3/61 4/50 4/41 8/38 ADENOMA OR CARCINOMA 4/61 6/50 6/41 10/38
|
Neoplastic Lesions
|
Yes
|
TR-528
|
3296-90-0 |
Fish project 1 (2,2-bis(Bromomethyl)-1,3-propanediol) |
Fish |
Medaka (Oryzias latipes) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
ADENOMA 1/27 0/21 1/31 3/29 ADENOMA OR CARCINOMA 1/27 0/21 1/31 4/29
|
Neoplastic Lesions
|
Yes
|
TR-528
|
3296-90-0 |
Fish project 1 (2,2-bis(Bromomethyl)-1,3-propanediol) |
Fish |
Medaka (Oryzias latipes) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
ADENOMA 1/47 0/59 0/56 6/59 ADENOMA OR CARCINOMA 1/47 0/59 0/56 8/59
|
Neoplastic Lesions
|
Yes
|
TR-528
|
3296-90-0 |
Fish project 1 (2,2-bis(Bromomethyl)-1,3-propanediol) |
Fish |
Guppy (Poecilia reticulata) |
Male |
Aquatic |
Liver
|
Positive |
Positive |
ADENOMA 0/28 3/22 3/21 6/24 ADENOMA OR CARCINOMA 0/28 3/22 3/21 9/24
|
Neoplastic Lesions
|
No
|
TR-528
|
75-52-5 |
Fish Project 1 (Nitromethane) |
Fish |
Guppy (Poecilia reticulata) |
Male |
Aquatic |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-528
|
75-52-5 |
Fish Project 1 (Nitromethane) |
Fish |
Guppy (Poecilia reticulata) |
Female |
Aquatic |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-528
|
75-52-5 |
Fish Project 1 (Nitromethane) |
Fish |
Medaka (Oryzias latipes) |
Female |
Aquatic |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-528
|
75-52-5 |
Fish Project 1 (Nitromethane) |
Fish |
Medaka (Oryzias latipes) |
Male |
Aquatic |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-541
|
75-12-7 |
Formamide |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-541
|
75-12-7 |
Formamide |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
adenoma or carcinoma 9/50, 15/50, 13/50, 18/50
|
May Have Been Related
|
Yes
|
TR-541
|
75-12-7 |
Formamide |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hemangiosarcoma (1/50, 5/50, 7/50, 8/50)
|
Neoplastic Lesions
|
No
|
TR-496
|
116355-83-0 |
Fumonisin B1 |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-496
|
116355-83-0 |
Fumonisin B1 |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
Adenoma 0/48 0/40 0/48 2/48 5/48 or Carcinoma 0/48 0/40 0/48 7/48 10/48 Combined 0/48 0/40 0/48 9/48 15/48
|
Neoplastic Lesions
|
Yes
|
TR-496
|
116355-83-0 |
Fumonisin B1 |
Mice |
MV |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 5/47 3/48 1/48 16/47 31/45 or Carcinoma 0/47 0/48 0/48 10/47 9/45 Combined 5/47 3/48 1/48 19/47 39/45
|
Neoplastic Lesions
|
No
|
TR-402
|
110-00-9 |
Furan |
Mice |
B6C3F1 |
Female |
Gavage |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 2/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-402
|
110-00-9 |
Furan |
Mice |
B6C3F1 |
Male |
Gavage |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 1/49 6/50 10/50
|
Neoplastic Lesions
|
No
|
TR-402
|
110-00-9 |
Furan |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 8/50 9/50 17/50 21/50
|
Neoplastic Lesions
|
No
|
TR-402
|
110-00-9 |
Furan |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 8/50 11/50 17/50 25/50
|
Neoplastic Lesions
|
Yes
|
TR-402
|
110-00-9 |
Furan |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 31/50 48/50, CARCINOMA 2/50 7/50 27/50, COMBINED 7/50 34/50 50/50
|
Neoplastic Lesions
|
Yes
|
TR-402
|
110-00-9 |
Furan |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 20/50 33/50 42/50, CARCINOMA 7/50 32/50 34/50, COMBINED 26/50 44/50 50/50
|
Neoplastic Lesions
|
Yes
|
TR-402
|
110-00-9 |
Furan |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 4/50 7/50, CARCINOMA 0/50 0/50 0/50 1/50, COMBINED 0/50 2/50 4/50 8/50; CHOLANGIOCARCINOMA 0/50 49/50 50/50 48/50
|
Neoplastic Lesions
|
Yes
|
TR-402
|
110-00-9 |
Furan |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 4/50 18/50 27/50, CARCINOMA 0/50 1/50 6/50 18/50, COMBINED 1/50 5/50 22/50 35/50; CHOLANGIOCARCINOMA 0/50 43/50 48/50 49/50
|
Neoplastic Lesions
|
No
|
TR-382
|
98-01-1 |
Furfural |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 1/50 6/50
|
May Have Been Related
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 1/49 1/50 OR CARCINOMA 0/50 1/50 0/49 0/50 COMBINED 0/50 1/50 1/49 1/50
|
May Have Been Related
|
Yes
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 13/50 11/49 19/50; CARCINOMA 7/50 12/50 6/49 21/50
|
Neoplastic Lesions
|
Yes
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 3/50 5/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-382
|
98-01-1 |
Furfural |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
CHOLANGIOCARCINOMA 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Male |
Gavage |
All Organs
|
Some Evidence |
Equivocal Evidence |
Mononuclear Cell Leukemia 9/50, 12/50, 22/50, 21/50
|
May Have Been Related
|
Yes
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Some Evidence |
Equivocal Evidence |
hepatocellular adenoma 0/50, 3/50, 3/50, 0/50
|
May Have Been Related
|
Yes
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 17/50, 37/50, 41/50, 48/50; hepatocellular carcinoma 9/50, 10/50, 15/50, 44/50; hepatoblastoma 1/50, 1/50, 8/50, 11/50
|
Neoplastic Lesions
|
Yes
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 22/50, 31/50, 41/50, 47/50; hepatoblastoma 3/50, 28/50, 36/50, 38/50
|
Neoplastic Lesions
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Some Evidence |
Equivocal Evidence |
respiratory epithelium, adenoma 0/49, 0/49, 2/50, 0/46
|
May Have Been Related
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Mice |
B6C3F1/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/50, 0/50, 2/50, 2/50
|
Neoplastic Lesions
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
adenoma 1/49, 0/50, 3/49, 1/49; follicular cell, carcinoma 0/49, 0/50, 1/49, 1/49
|
Neoplastic Lesions
|
No
|
TR-578
|
90045-36-6 |
Ginkgo biloba extract |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
adenoma 2/50, 1/50, 3/49, 5/45
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Epididymis
|
Clear Evidence |
Equivocal Evidence |
SARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 13/50 14/50 20/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 3/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 3/50 6/50
|
Neoplastic Lesions
|
No
|
TR-562
|
GOLDENSEALRT |
Goldenseal root powder |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-562
|
GOLDENSEALRT |
Goldenseal root powder |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma: 0/50 0/50 1/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-562
|
GOLDENSEALRT |
Goldenseal root powder |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma: 1/50 1/50 2/50 10/50 adenoma or carcinoma 1/50 1/50 2/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-562
|
GOLDENSEALRT |
Goldenseal root powder |
Mice |
B6C3F1/N |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
Hepatoblastoma 1/50 2/50 1/5 6/50 multiple adenoma 3/50 5/50 11/50 18/50
|
Neoplastic Lesions
|
Yes
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 24/48 47/49
|
Neoplastic Lesions
|
Yes
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 11/50 20/50 30/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
NEOPLASTIC NODULE 0/49 0/50 3/50; CARCINOMA 1/49 0/50 6/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Rats |
F344/N |
Female |
Dosed-Feed |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/49 3/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/49 4/50 COMBINED 1/50 3/49 7/50
|
Neoplastic Lesions
|
No
|
TR-271
|
2784-94-3 |
HC Blue 1 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/47 0/49 5/50
|
May Have Been Related
|
No
|
TR-009
|
76-44-8 |
Heptachlor |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-009
|
76-44-8 |
Heptachlor |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-009
|
76-44-8 |
Heptachlor |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-009
|
76-44-8 |
Heptachlor |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-068
|
67-72-1 |
Hexachloroethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-068
|
67-72-1 |
Hexachloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-068
|
67-72-1 |
Hexachloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-068
|
67-72-1 |
Hexachloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-092
|
122-66-7 |
Hydrazobenzene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-092
|
122-66-7 |
Hydrazobenzene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-092
|
122-66-7 |
Hydrazobenzene |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE)
|
Neoplastic Lesions
|
Yes
|
TR-092
|
122-66-7 |
Hydrazobenzene |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-092
|
122-66-7 |
Hydrazobenzene |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-092
|
122-66-7 |
Hydrazobenzene |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-366
|
123-31-9 |
Hydroquinone |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
Leukemia 9/55 15/55 22/55
|
Neoplastic Lesions
|
No
|
TR-366
|
123-31-9 |
Hydroquinone |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
Adenoma 0/55 4/55 8/55
|
Neoplastic Lesions
|
Yes
|
TR-366
|
123-31-9 |
Hydroquinone |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
Adenoma 2/55 15/55 12/55; adenoma or carcinoma (combined) 3/55 16/55 13/55
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
BENIGN PHEOCHROMOCYTOMA 2/50 6/48 2/50 9/49
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
BENIGN PHEOCHROMOCYTOMA 10/50 22/50 16/49 23/50 BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 10/50 26/50 18/49 24/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 14/50 21/50 14/50 24/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 16/50 23/50 29/50 25/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 5/50 3/50; ADEMONA OR CARCINOMA 1/50 2/50 6/50 3/50
|
May Have Been Related
|
Yes
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 12/50 14/50 18/50 14/50; CARCINOMA 6/50 17/50 8/50 10/50; COMBINED 18/50 28/50 24/50 23/50
|
Neoplastic Lesions
|
Yes
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/50 24/50 23/50 32/50; CARCINOMA 11/50 22/50 23/50 16/50; COMBINED 26/50 40/50 37/50 39/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADEMONA 3/50 6/50 10/50 7/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 6/50 5/50 7/50; COMBINED 4/50 11/50 15/50 14/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 15/50 22/50 13/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADEMONA 0/50 7/50 5/50 19/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 3/50 1/50 11/50; COMBINED 1/50 10/50 6/50 26/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADEMONA 6/50 13/50 27/50 30/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 10/50 8/50 16/50; COMBINED 7/50 22/50 30/50 35/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 8/50 3/50 2/50
|
May Have Been Related
|
No
|
TR-499
|
22398-80-7 |
Indium phosphide |
Rats |
F344/N |
Male |
Inhalation |
Skin
|
Clear Evidence |
Equivocal Evidence |
FIBROMA 1/50 4/50 7/50 3/50; FIBROMA OR FIBROSARCOMA 2/50 4/50 8/50 4/50
|
May Have Been Related
|
Yes
|
TR-584
|
700-06-1 |
Indole-3-carbinol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 26/50 32/50 31/49 41/50 hepatocellular carcinoma 12/50 11/50 29/49 14/50 hepatoblastoma 3/50 4/50 4/49 14/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 36/50 36/50 44/49 45/50
|
Neoplastic Lesions
|
No
|
TR-584
|
700-06-1 |
Indole-3-carbinol |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Skin
|
Some Evidence |
Equivocal Evidence |
fibroma 1/50 0/50 0/50 4/50 fibrosarcoma 1/50 0/50 0/50 1/50 fibroma or fibrosarcoma 2/50 0/50 0/50 5/50
|
May Have Been Related
|
No
|
TR-584
|
700-06-1 |
Indole-3-carbinol |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus
|
Some Evidence |
Some Evidence |
adenocarcinoma (standard evaluation) 0/50 1/50 4/50 4/50 (standard and extended evaluations) combined 5/50 4/50 13/50 10/50
|
Neoplastic Lesions
|
No
|
TR-551
|
97-54-1 |
Isoeugenol |
Mice |
B6C3F1/N |
Female |
Gavage |
All Organs
|
Equivocal Evidence |
Equivocal Evidence |
Histiocytic sarcoma 0/49 1/50 1/50 4/50
|
May Have Been Related
|
Yes
|
TR-551
|
97-54-1 |
Isoeugenol |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 24/50 35/50 37/50 33/50 carcinoma 8/50 18/50 19/50 18/50 adenoma or carcinoma 28/50 43/50 43/50 43/50
|
Neoplastic Lesions
|
No
|
TR-551
|
97-54-1 |
Isoeugenol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Equivocal Evidence |
Equivocal Evidence |
Carcinoma 0/50 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-551
|
97-54-1 |
Isoeugenol |
Rats |
F344/N |
Male |
Gavage |
Thymus
|
Equivocal Evidence |
Equivocal Evidence |
Thymoma, benign or malignant 0/47 0/43 0/49 2/48
|
May Have Been Related
|
Yes
|
TR-571
|
9000-38-8 |
Kava kava extract |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Hepatocellular carcinoma 3/50 13/50 8/50 8/50 hepatocellular adenoma or carcinoma 10/50 21/50 20/50 13/50
|
Neoplastic Lesions
|
Yes
|
TR-571
|
9000-38-8 |
Kava kava extract |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Hepatoblastoma 0/50 4/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-571
|
9000-38-8 |
Kava kava extract |
Rats |
F344/N |
Male |
Gavage |
Testis
|
Equivocal Evidence |
Equivocal Evidence |
Interstitial cell adenoma 37/49 44/50 49/50 46/50
|
May Have Been Related
|
No
|
TR-039
|
303-34-4 |
Lasiocarpine |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Positive |
Positive |
Lymphoma/Leukemia
|
Neoplastic Lesions
|
Yes
|
TR-039
|
303-34-4 |
Lasiocarpine |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
Angiosarcoma, carcinoma, adenoma
|
Neoplastic Lesions
|
Yes
|
TR-039
|
303-34-4 |
Lasiocarpine |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
Angiosarcoma, carcinoma, adenoma
|
Neoplastic Lesions
|
Yes
|
TR-480
|
120-40-1 |
Lauric acid diethanolamine condensate |
Mice |
B6C3F1 |
Female |
Topical Application |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 23/50 32/49 29/50 ADENOMA OR CARCINOMA COMBINED 28/50 40/49 36/50
|
Neoplastic Lesions
|
No
|
TR-527
|
129-73-7 |
Leucomalachite green |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
HEPATOCELLULAR ADENOMA 1/48 3/48 0/48 3/48
|
Neoplastic Lesions
|
Yes
|
TR-527
|
129-73-7 |
Leucomalachite green |
Mice |
MV |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA OR CARCINOMA 3/47 6/48 6/47 11/47
|
Neoplastic Lesions
|
No
|
TR-527
|
129-73-7 |
Leucomalachite green |
Rats |
F344/N |
Male |
Dosed-Feed |
Testis
|
Equivocal Evidence |
Equivocal Evidence |
INTERSTITIAL CELL ADENOMA 37/48 42/47 43/48 45/47 BILATERAL INTERSTITIAL CELL ADEMONA 22/48 30/47 38/48 39/47
|
Neoplastic Lesions
|
No
|
TR-527
|
129-73-7 |
Leucomalachite green |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
CARCINOMA OR ADENOMA 0/46 1/46 2/47 1/48
|
Neoplastic Lesions
|
No
|
TR-527
|
129-73-7 |
Leucomalachite green |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/47 2/47 1/48 3/46
|
Neoplastic Lesions
|
No
|
TR-527
|
569-64-2 |
Malachite green |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 1/48 1/48 3/48 4/48
|
Neoplastic Lesions
|
No
|
TR-527
|
569-64-2 |
Malachite green |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Equivocal Evidence |
Equivocal Evidence |
CARCINOMA 2/48 2/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-527
|
569-64-2 |
Malachite green |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/46 0/48 3/47 2/46
|
Neoplastic Lesions
|
Yes
|
TR-328
|
598-55-0 |
Methyl carbamate |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/50 5/49; CARCINOMA 0/50 0/50 1/50
|
Neoplastic Lesions
|
Yes
|
TR-328
|
598-55-0 |
Methyl carbamate |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 3/50 0/50 3/49; CARCINOMA 1/50 0/50 4/49
|
Neoplastic Lesions
|
No
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Some Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 25/50 26/50 32/50 35/50
|
May Have Been Related
|
No
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Rats |
F344/N |
Female |
Inhalation |
Kidney Mesenchymal Cell
|
Equivocal Evidence |
Equivocal Evidence |
TUMOR MALIGNANT 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA (STANDARD EVALUATION - 0/50 0/50 2/50 3/50; STANDARD AND EXTENDED EVAULATION COMBINED - 2/50 3/50 3/50 10/50); CARCINOMA (STANDARD EVALUATION - 0/50 1/50 0/50 2/50); ADENOMA OR CARCINOMA (COMBINED) (STANDARD EVAULATION - 0/50 1/50 2/50 4/50; STANDARD AND EXTENDED EVALUATION - 2/50 4/50 3/50 11/50)
|
Neoplastic Lesions
|
Yes
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 13/50 15/50 20/50 23/50 ADENOMA OR CARCINOMA (COMBINED) 17/50 17/50 22/50 27/50
|
Neoplastic Lesions
|
Yes
|
TR-538
|
108-10-1 |
Methyl isobutyl ketone |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 17/50 25/50 23/50 34/50 ADENOMA OR CARCINOMA (COMBINED) 27/50 34/50 28/50 37/50
|
Neoplastic Lesions
|
Yes
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 6/48 22/48 OR CARCINOMA 1/50 11/48 32/48 COMBINED 3/50 16/48 40/48
|
Neoplastic Lesions
|
Yes
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 14/49 14/49 OR CARCINOMA 13/50 15/49 26/49 COMBINED 22/50 24/49 33/49
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 23/48 28/48; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 13/48 29/48
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 19/50 24/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 10/50 28/50
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 5/50 11/50 13/50 22/50 COMBINED 5/50 11/50 13/50 23/50
|
Neoplastic Lesions
|
No
|
TR-306
|
75-09-2 |
Methylene chloride |
Rats |
F344/N |
Male |
Inhalation |
Mammary Gland
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 0/50 0/50 2/50 4/50 COMBINED 0/50 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Male |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50
|
Neoplastic Lesions
|
Yes
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50
|
Neoplastic Lesions
|
Yes
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 5/50 5/50 15/50 13/50 6/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50
|
Neoplastic Lesions
|
No
|
TR-439
|
298-59-9 |
Methylphenidate hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-439
|
298-59-9 |
Methylphenidate hydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
HEPATOCELLULAR ADENOMA 6/49 10/48 10/49 28/50 CARCINOMA 5/49 3/48 2/49 6/50 COMBINED 9/49 11/48 11/49 30/50
|
Neoplastic Lesions
|
Yes
|
TR-439
|
298-59-9 |
Methylphenidate hydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
HEPATOCELLULAR ADENOMA 18/50 18/50 16/50 29/50 CARCINOMA 10/50 9/50 17/50 11/50 COMBINED 24/50 23/50 26/50 34/50; HEPATOBLASTOMA 0/50 1/50 1/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-181
|
90-94-8 |
Michler's ketone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-181
|
90-94-8 |
Michler's ketone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-181
|
90-94-8 |
Michler's ketone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-181
|
90-94-8 |
Michler's ketone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-313
|
2385-85-5 |
Mirex |
Rats |
F344/N |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 8/51 7/52 13/52 11/52 18/51 19/51
|
Neoplastic Lesions
|
No
|
TR-313
|
2385-85-5 |
Mirex |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 6/52 9/52 14/52
|
Neoplastic Lesions
|
No
|
TR-313
|
2385-85-5 |
Mirex |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/51 0/51 0/52 0/52 1/51 3/52
|
Neoplastic Lesions
|
Yes
|
TR-313
|
2385-85-5 |
Mirex |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 2/52 23/52 30/52
|
Neoplastic Lesions
|
Yes
|
TR-313
|
2385-85-5 |
Mirex |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 3/52 5/52 5/52 14/52 15/52 26/52
|
Neoplastic Lesions
|
No
|
TR-266
|
150-68-5 |
Monuron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-266
|
150-68-5 |
Monuron |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-266
|
150-68-5 |
Monuron |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 7/50 OR ADENOCARCINOMA 0/50 1/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-266
|
150-68-5 |
Monuron |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/50 6/49 7/50 OR CARCINOMA 0/50 1/49 3/50 COMBINED 1/50 6/49 9/50
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Rats |
F344/N |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/47 8/45 20/48
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/48 14/49 29/50
|
Neoplastic Lesions
|
Yes
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 4/50 17/49
|
Neoplastic Lesions
|
Yes
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 4/50 19/50 OR CARCINOMA 6/50 13/50 12/50 COMBINED 12/50 17/50 26/50
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 4/50 7/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 5/50 7/49 COMBINED 6/50 8/50 13/49
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 6/50 11/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/49 4/50 10/50 COMBINED 5/49 10/50 18/50
|
Neoplastic Lesions
|
No
|
TR-352
|
924-42-5 |
N-Methylolacrylamide |
Mice |
B6C3F1 |
Female |
Gavage |
Ovary
|
Clear Evidence |
Clear Evidence |
GRANULOSA CELL TUMOR 0/50 5/45 5/47
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 1/50, 5/50, 6/50, 7/50; squamous cell papilloma or carcinoma 1/50, 6/50, 6/50, 7/50
|
Neoplastic Lesions
|
Yes
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 17/50, 19/50, 37/50, 44/50; hepatocellular carcinoma 6/50, 13/50, 18/50, 31/50; hepatoblastoma 0/50, 1/50, 0/50, 4/50
|
Neoplastic Lesions
|
Yes
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma, multiple 17/50, 19/50, 27/50, 26/50; hepatocellular carcinoma 22/50, 25/50, 30/50, 36/50; hepatoblastoma 1/50, 5/50, 10/50, 8/50
|
Neoplastic Lesions
|
Yes
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 0/50, 4/49; hepatocellular adenoma or carcinoma 0/50, 1/50, 1/50, 7/49
|
Neoplastic Lesions
|
Yes
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 1/50, 6/50; hepatocellular adenoma or carcinoma 0/50, 0/50, 2/50, 6/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 2/50, 4/50, 8/50, 12/50; alveolar/bronchiolar adenoma or carcinoma 2/50, 5/50, 9/50, 13/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 1/49, 0/50, 2/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 3/49, 2/50, 11/49; transitional epithelium, adenoma or carcinoma 0/50, 3/49, 2/50, 13/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma 1/50, 2/49, 2/50, 4/49
|
May Have Been Related
|
No
|
TR-146
|
139-94-6 |
Nithiazide |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-146
|
139-94-6 |
Nithiazide |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-146
|
139-94-6 |
Nithiazide |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-146
|
139-94-6 |
Nithiazide |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(FIBROADENOMA OR CYSTADENOMA)
|
Neoplastic Lesions
|
No
|
TR-146
|
139-94-6 |
Nithiazide |
Rats |
F344/N |
Female |
Dosed-Feed |
Skin
|
Positive |
Positive |
(FIBROADENOMA OR CYSTADENOMA)
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-184
|
1836-75-5 |
Nitrofen |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-184
|
1836-75-5 |
Nitrofen |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-184
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
HEPATOCELLULAR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
HEPATOCELLULAR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-184
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Liver)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Liver)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Rats |
F344/N |
Male |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 7/50 16/50 19/50 OR CARCINOMA 1/50 2/50 4/50 3/50 COMBINED 6/50 9/50 20/50 21/50
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 10/50 19/50 32/50 OR CARCINOMA 1/50 1/50 6/50 5/50 COMBINED 10/50 11/50 25/50 37/50
|
Neoplastic Lesions
|
Yes
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/50 25/50 17/50 35/50 OR CARCINOMA 10/50 14/50 8/50 12/50 COMBINED 19/50 34/50 22/50 40/50
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 3/50 2/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 3/50 5/50 3/50 COMBINED 3/50 6/50 6/50 12/50
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR ADENOMA 11/50 10/50 9/50 12/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 3/50 3/50 11/50 COMBINED 13/50 13/50 12/50 20/50
|
Neoplastic Lesions
|
No
|
TR-461
|
75-52-5 |
Nitromethane |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 19/50 21/50 33/50 36/50 OR CARCINOMA 2/50 7/50 1/50 11/50 COMBINED 9/50 25/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 0/50 1/50
|
May Have Been Related
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA O/50 0/50 1/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 14/50 11/50 14/50 26/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 26/50 25/50 42/50 34/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) ADENOMATOUS POLYP 0/60 8/60 18/60, CARCINOMA 0/60 0/60 2/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) ADENOMATOUS POLYP 0/60 26/60 30/60, CARCINOMA 0/60 0/60 5/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Transitional Cell
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) PAPILLOMA 0/60 0/60 1/60 OR CARCINOMA 0/60 0/60 1/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Clear Evidence |
Clear Evidence |
PAPILLOMA (STOP STUDY) 0/60 0/60 4/60 OR CARCINOMA 0/60 1/60 8/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 1/50 1/50 1/49 OR CARCINOMA 0/49 0/50 0/50 2/49
|
May Have Been Related
|
Yes
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/50 26/50 41/50 29/50; CARCINOMA 7/50 12/50 11/50 7/50; HEPATOBLASTOMA 0/50 3/50 17/50 9/50
|
Neoplastic Lesions
|
Yes
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 14/50 2/50 36/50 18/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/58 2/59 1/60, TRANSITIONAL CELL CARCINOMA 0/58 28/59 48/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/59 9/59 1/60, TRANSITIONAL CELL CARCINOMA 0/59 27/59 50/60, SQUAMOUS CELL PAPILLOMA 0/59 0/59 4/60, SQUAMOUS CELL CARCINOMA 0/59 0/59 6/60, SARCOMA 0/59 2/59 9/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/60 2/60 3/60 50/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 4/60 17/60 55/60 60/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(CECUM) CARCINOMA 0/60 1/60 4/60 3/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(CECUM) CARCINOMA 0/60 12/60 9/60 0/60
|
Neoplastic Lesions
|
Yes
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/60 0/59 1/60 6/60
|
May Have Been Related
|
Yes
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/60 5/59 19/59 29/60 CARCINOMA 2/60 4/59 6/59 16/60 COMBINED 9/60 9/59 24/59 39/60
|
Neoplastic Lesions
|
Yes
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/60 3/60 3/60 7/60 3/60 4/60 ADENOMA OR CARCINOMA 3/60 3/60 3/60 8/60 3/60 6/60 CHOLANGIOCARCINOMA 0/60 0/60 0/60 0/60 0/60 3/60 HEPATOCHOLANGIOCARCINOMA 0/60 1/60 0/60 1/60 0/60 0/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 5/60 1/60 2/60 3/60 8/60 OR ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/60 5/60 1/60 2/60 3/60 11/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 23/60 47/60 52/60 56/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Female |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
(SUBCUTANEOUS) FIBROMA 3/60 3/60 18/60 20/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60
|
Neoplastic Lesions
|
No
|
TR-504
|
88-72-2 |
o-Nitrotoluene |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
(SUBCUTANEOUS) LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60
|
Neoplastic Lesions
|
Yes
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOMA OR FIBROADENOMA)
|
Neoplastic Lesions
|
No
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Positive |
Positive |
MESOTHELIOMA
|
Neoplastic Lesions
|
No
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Spleen
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Spleen
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Positive |
Positive |
(FIBROMA)
|
Neoplastic Lesions
|
No
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-153
|
636-21-5 |
o-Toluidine hydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
Yes
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 0/60 22/59 47/59; CARCINOMA 1/60 1/59 11/59; (B6C3F1) ADENOMA 25/50 35/50 35/50 36/50; CARCINOMA 9/50 5/50 49/50 44/50; HEPATOBLASTOMA 0/50 1/50 8/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
Swiss Webster |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 0/60 22/59 47/59; CARCINOMA 1/60 1/59 11/59; (B6C3F1) ADENOMA 25/50 35/50 35/50 36/50; CARCINOMA 9/50 5/50 49/50 44/50; HEPATOBLASTOMA 0/50 1/50 8/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
Swiss Webster |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 1/60 35/60 50/60; CARCINOMA 0/60 5/60 19/60; (B6C3F1) ADENOMA 17/49 18/50 34/50 32/50; CARCINOMA 9/49 5/50 45/50 50/50; HEPATOBLASTOMA 0/49 2/50 21/50 13/50
|
Neoplastic Lesions
|
Yes
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
(SWISS-WEBSTER) ADENOMA 1/60 35/60 50/60; CARCINOMA 0/60 5/60 19/60; (B6C3F1) ADENOMA 17/49 18/50 34/50 32/50; CARCINOMA 9/49 5/50 45/50 50/50; HEPATOBLASTOMA 0/49 2/50 21/50 13/50
|
Neoplastic Lesions
|
No
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
Swiss Webster |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-443
|
604-75-1 |
Oxazepam |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Male |
Gavage |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 19/51 21/50 21/50 29/49 COMBINED 19/51 25/50 21/50 29/49
|
May Have Been Related
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA (STANDARD) 0/51 1/50 0/50 2/49 (EXTENDED) 4/51 12/50 1/50 5/49 COMBINED 4/51 13/50 1/50 6/49
|
May Have Been Related
|
Yes
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 1/50 1/50 8/49 COMBINED 1/50 1/50 1/50 10/49
|
Neoplastic Lesions
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ADEMONA 0/50 0/50 6/50 1/49 COMBINED 0/50 0/50 7/50 1/49
|
Neoplastic Lesions
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Equivocal Evidence |
Equivocal Evidence |
FIBROMA 0/51 5/50 2/49 2/50 COMBINED 0/51 7/50 2/49 2/50
|
May Have Been Related
|
No
|
TR-485
|
434-07-1 |
Oxymetholone |
Rats |
F344/N |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
COMBINED 0/50 0/50 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Female |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
benign pheochromocytoma (0/49, 3/50, 4/50, 6/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma (2/50, 6/50, 6/50, 8/50); adenoma or adenocarcinoma (2/50, 6/50, 9/50, 8/50)
|
Neoplastic Lesions
|
Yes
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (12/50, 14/50, 24/50, 34/50); hepatocellular carcinoma (7/50, 8/50, 12/50, 34/50); hepatoblastoma (0/50, 0/50, 1/50, 8/50)
|
Neoplastic Lesions
|
Yes
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma (8/50, 19/50, 16/50, 35/50); hepatoblastoma (1/50, 1/50, 1/50, 15/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Male |
Inhalation |
Lung
|
Some Evidence |
Equivocal Evidence |
alveolar/bronchiolar adenoma or carcinoma (0/50, 2/50, 0/50, 3/50)
|
May Have Been Related
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Female |
Inhalation |
Thyroid Gland C-Cell
|
Some Evidence |
Some Evidence |
adenoma (2/50, 8/50, 8/50, 14/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Male |
Inhalation |
Thyroid Gland C-Cell
|
Some Evidence |
Some Evidence |
adenoma (2/50, 5/49, 3/49, 12/50)
|
Neoplastic Lesions
|
No
|
TR-594
|
98-56-6 |
p-Chloro-a,a,a-trifluorotoluene |
Rats |
Harlan Sprague-Dawley |
Female |
Inhalation |
Uterus
|
Some Evidence |
Some Evidence |
adenocarcinoma (1/50, 1/50, 0/50, 5/50); stromal polyp (7/50, 9/50, 16/50, 12/50)
|
Neoplastic Lesions
|
No
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Rats |
F344/N |
Male |
Gavage |
Adrenal Gland Medulla
|
Clear Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 13/49 14/48 15/48 26/49
|
May Have Been Related
|
No
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Rats |
F344/N |
Female |
Gavage |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 2/50 3/50 1/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 9/50 15/49 10/50 44/50 OR CARCINOMA 3/50 7/49 11/50 17/50 COMBINED 11/50 21/49 20/50 21/50
|
Neoplastic Lesions
|
No
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Rats |
F344/N |
Male |
Gavage |
Spleen
|
Clear Evidence |
Clear Evidence |
FIBROSARCOMA 0/49 1/50 2/50 17/50, HEMANGIOSARCOMA 0/49 0/50 0/50 4/50, OR OSTEOSARCOMA 0/49 0/50 1/50 19/50 COMBINED 0/49 1/50 3/50 38/50
|
Neoplastic Lesions
|
No
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Rats |
F344/N |
Female |
Gavage |
Spleen
|
Equivocal Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 1/50 0/50 OR OSTEOSARCOMA 0/50 0/50 0/50 1/50 COMBINED 0/50 0/50 1/50 1/50
|
Neoplastic Lesions
|
No
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Mice |
B6C3F1 |
Male |
Gavage |
Vascular System (Liver)
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 2/50 2/50 1/49 6/50
|
Neoplastic Lesions
|
No
|
TR-351
|
20265-96-7 |
p-Chloroaniline hydrochloride |
Mice |
B6C3F1 |
Male |
Gavage |
Vascular System (Spleen)
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 3/50 2/47 0/49 5/49
|
Neoplastic Lesions
|
Yes
|
TR-142
|
120-71-8 |
p-Cresidine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-142
|
120-71-8 |
p-Cresidine |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-142
|
120-71-8 |
p-Cresidine |
Rats |
F344/N |
Female |
Dosed-Feed |
Nasal Cavity
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-142
|
120-71-8 |
p-Cresidine |
Rats |
F344/N |
Male |
Dosed-Feed |
Nasal Cavity
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
No
|
TR-142
|
120-71-8 |
p-Cresidine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-142
|
120-71-8 |
p-Cresidine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-142
|
120-71-8 |
p-Cresidine |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(PAPILLOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-142
|
120-71-8 |
p-Cresidine |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(PAPILLOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-190
|
156-10-5 |
p-Nitrosodiphenylamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-190
|
156-10-5 |
p-Nitrosodiphenylamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-190
|
156-10-5 |
p-Nitrosodiphenylamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-190
|
156-10-5 |
p-Nitrosodiphenylamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-131
|
72-55-9 |
p,p'-Dichlorodiphenyl dichloroethylene |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-131
|
72-55-9 |
p,p'-Dichlorodiphenyl dichloroethylene |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-131
|
72-55-9 |
p,p'-Dichlorodiphenyl dichloroethylene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-131
|
72-55-9 |
p,p'-Dichlorodiphenyl dichloroethylene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 5/50 7/49 32/50 46/49 hepatocellular carcinoma 4/50 2/49 6/50 27/49 hepatocellular adenoma or carcinoma 8/50 8/49 33/50 47/49
|
Neoplastic Lesions
|
Yes
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 23/50 35/50 49/50 40/50 hepatocellular carcinoma 18/50 15/50 30/50 45/50 hepatocellular adenoma or carcinoma 31/50 40/50 49/50 47/50 hepatoblastoma 1/50 1/50 16/50 5/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 31/50 40/50 49/50 47/50
|
Neoplastic Lesions
|
Yes
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
cholangiocarcinoma 0/50 0/49 0/50 2/47 hepatocholangioma 0/50 0/49 0/50 8/47 hepatocellular adenoma 3/50 2/49 8/50 16/47 hepatocellular carcinoma 0/50 0/49 1/50 6/47 hepatocellular adenoma or carcinoma 3/50 2/49 8/50 17/47) hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/50 2/49 8/50 21/47
|
Neoplastic Lesions
|
Yes
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma or carcinoma 3/49 2/50 4/50 9/50; hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/49 2/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
(pars distalis): adenoma 19/49 12/49 22/50 35/50
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/45 3/45 2/48 6/46
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Female |
Gavage |
Uterus
|
Clear Evidence |
Equivocal Evidence |
stromal polyp or stromal sarcoma (original and residual evaluations, combined) 4/50 12/50 12/50 9/49
|
May Have Been Related
|
No
|
TR-232
|
76-01-7 |
Pentachloroethane |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-232
|
76-01-7 |
Pentachloroethane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal |
ADENOMA 0/50 1/49 4/50; ADENOMA OR ADENOCARCINOMA COMBINED 1/50 2/49 4/50
|
Neoplastic Lesions
|
Yes
|
TR-232
|
76-01-7 |
Pentachloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
ADENOMA 2/46 8/42 19/45; CARCINOMA 1/46 28/42 13/45
|
Neoplastic Lesions
|
Yes
|
TR-232
|
76-01-7 |
Pentachloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 4/48 26/44 7/45
|
Neoplastic Lesions
|
No
|
TR-349
|
87-86-5 |
Pentachlorophenol, Dowicide EC-7 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 0/35 2/49 2/46 38/49
|
Neoplastic Lesions
|
No
|
TR-349
|
87-86-5 |
Pentachlorophenol, Dowicide EC-7 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 0/34 4/48 21/48 44/49 OR MALIGNANT PHEOCHROMOCYTOMA 1/34 0/48 0/48 3/49 COMBINED 1/34 4/48 21/48 45/49
|
Neoplastic Lesions
|
Yes
|
TR-349
|
87-86-5 |
Pentachlorophenol, Dowicide EC-7 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/34 3/50 6/49 30/48 OR CARCINOMA 0/34 1/50 0/49 1/48 COMBINED 1/34 4/50 6/49 31/48
|
Neoplastic Lesions
|
Yes
|
TR-349
|
87-86-5 |
Pentachlorophenol, Dowicide EC-7 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/35 13/48 17/48 32/49 OR CARCINOMA 1/35 7/48 7/48 9/49 COMBINED 6/35 19/48 21/48 34/49
|
Neoplastic Lesions
|
No
|
TR-349
|
87-86-5 |
Pentachlorophenol, Dowicide EC-7 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Liver)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/34 1/50 1/49 8/48
|
Neoplastic Lesions
|
No
|
TR-349
|
87-86-5 |
Pentachlorophenol, Dowicide EC-7 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Spleen)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/34 0/50 2/50 2/47
|
Neoplastic Lesions
|
No
|
TR-349
|
87-86-5 |
Pentachlorophenol, technical |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
PHEOCHROMOCYTOMA 0/31 10/45 23/45
|
Neoplastic Lesions
|
Yes
|
TR-349
|
87-86-5 |
Pentachlorophenol, technical |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/32 20/47 33/48 OR CARCINOMA 2/32 10/47 12/48 COMBINED 7/32 26/47 37/48
|
Neoplastic Lesions
|
Yes
|
TR-349
|
87-86-5 |
Pentachlorophenol, technical |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 3/33 8/49 8/50 OR CARCINOMA 0/33 1/49 1/50 COMBINED 3/33 9/49 9/50
|
Neoplastic Lesions
|
No
|
TR-349
|
87-86-5 |
Pentachlorophenol, technical |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Liver)
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 0/33 2/49 4/50
|
Neoplastic Lesions
|
No
|
TR-349
|
87-86-5 |
Pentachlorophenol, technical |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Spleen)
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 0/33 1/50 3/47
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Unspecified
|
Clear Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Unspecified
|
Some Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
Perinatal + Postweaning: hepatocellular carcinoma (1/50, 0/50, 4/50)
|
May Have Been Related
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
Postweaning: hepatocellular carcinoma (1/50, 1/50, 3/49)
|
May Have Been Related
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Postweaning: hepatocellular adenoma (0/50, 0/50, 7/50, 11/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50); hepatocellular adenoma or carcinoma (0/50, 0/50, 7/50,11/50)
|
Neoplastic Lesions
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Perinatal + Postweaning: hepatocellular adenoma (0/50, 1/50, 5/50, 10/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 4/50); hepatocellular adenoma or carcinoma (0/50, 1/50, 5/50, 12/50)
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
Perinatal + Postweaning: acinar cell adenoma (7/50, 18/50, 30/50, 30/50); acinar cell adenocarcinoma (0/50, 2/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (7/50, 20/50, 30/50, 30/50)
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
Postweaning: acinar cell adenoma (3/50, 28/50, 26/50, 32/50); acinar cell adenocarcinoma (0/50, 3/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (3/50, 29/50, 26/50, 32/50)
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
Perinatal + Postweaning: acinar cell adenoma (0/50, 0/50, 3/50); acinar cell adenocarcinoma (0/50, 0/50, 2/50); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 5/50)
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
Postweaning: acinar cell adenoma (0/50, 0/50, 1/49); acinar cell adenocarcinoma (0/50, 0/50, 1/49); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 2/49)
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Some Evidence |
Equivocal Evidence |
Perinatal + Postweaning: adenocarcinoma (1/50, 3/50, 5/50)
|
May Have Been Related
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Some Evidence |
Equivocal Evidence |
Postweaning: adenocarcinoma (1/50, 5/50, 8/50)
|
May Have Been Related
|
No
|
TR-099
|
136-40-3 |
Phenazopyridine hydrochloride |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-099
|
136-40-3 |
Phenazopyridine hydrochloride |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-099
|
136-40-3 |
Phenazopyridine hydrochloride |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-099
|
136-40-3 |
Phenazopyridine hydrochloride |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Rats |
F344/N |
Female |
Gavage |
Kidney Transitional Cell
|
Some Evidence |
Some Evidence |
CARCINOMA 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA (STEP SECTIONS) 0/50 3/50 1/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 0/50 4/50 1/50
|
May Have Been Related
|
No
|
TR-367
|
50-33-9 |
Phenylbutazone |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/49 3/50 OR CARCINOMA 0/50 1/49 0/50 COMBINED 0/50 1/49 3/50
|
Neoplastic Lesions
|
Yes
|
TR-367
|
50-33-9 |
Phenylbutazone |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 8/50 12/50 24/50 OR CARCINOMA 8/50 4/50 11/50 COMBINED 16/50 14/50 31/50
|
Neoplastic Lesions
|
No
|
TR-124
|
120-62-7 |
Piperonyl sulfoxide |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-124
|
120-62-7 |
Piperonyl sulfoxide |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-124
|
120-62-7 |
Piperonyl sulfoxide |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-124
|
120-62-7 |
Piperonyl sulfoxide |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-398
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 39/50 46/48; CARCINOMA 1/50 22/50 35/48
|
Neoplastic Lesions
|
Yes
|
TR-398
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 48/49 42/50; CARCINOMA 8/50 30/49 36/50
|
Neoplastic Lesions
|
Yes
|
TR-398
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 10/50 38/50 OR CARCINOMA 0/50 2/50 4/50 COMBINED 0/50 12/50 39/50
|
Neoplastic Lesions
|
Yes
|
TR-398
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 10/49 38/50 OR CARCINOMA 0/50 2/49 19/50 COMBINED 1/50 12/49 41/50
|
Neoplastic Lesions
|
Yes
|
TR-244
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 0/13 0/19 2/15 2/11 3/17 7/8
|
Neoplastic Lesions
|
Yes
|
TR-244
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 12/25 8/27 8/24 12/25 15/23 21/22
|
Neoplastic Lesions
|
Yes
|
TR-244
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 0/20 2/21 0/21 2/11 5/19 8/20; CARCINOMA 0/20 0/21 0/21 0/11 3/19 7/20; CHOLANGIOCARCINOMA 0/20 0/21 0/21 0/11 0/19 7/20
|
Neoplastic Lesions
|
Yes
|
TR-244
|
67774-32-7 |
Polybrominated biphenyl mixture (Firemaster FF-1) |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 0/33 0/39 1/40 4/31 4/33 1/31; CARCINOMA 0/33 2/39 0/40 1/31 7/33 7/31; CHOLANGIOCARCINOMA 0/33 0/39 0/40 0/31 0/33 2/31
|
Neoplastic Lesions
|
No
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
(SINGLE SECTIONS) ADENOMA 2/50 1/50 1/50 1/50 OR CARCINOMA 0/50 0/50 0/50 1/50 COMBINED 2/50 1/50 1/50 2/50; (SINGLE AND STEP SECTIONS) ADENOMA 4/50 2/50 4/50 6/50 OR CARCINOMA 0/50 0/50 0/50 1/50 COMBINED 4/50 2/50 4/50 7/50
|
Neoplastic Lesions
|
Yes
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 15/50 42/50 45/49 47/50, CARCINOMA 3/50 11/50 19/49 38/50 OR HEPATOBLASTOMA 1/50 4/50 4/49 4/50 COMBINED 16/50 42/50 46/49 50/50
|
Neoplastic Lesions
|
Yes
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 22/50 41/50 39/50 32/50, CARCINOMA 12/50 31/50 35/50 38/50 OR HEPATOBLASTOMA 0/50 17/50 26/50 7/50 COMBINED 31/50 49/50 49/50 46/50
|
Neoplastic Lesions
|
No
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 3/48 3/50 6/50
|
Neoplastic Lesions
|
No
|
TR-476
|
125-33-7 |
Primidone (primaclone) |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 1/50 1/50 6/49 3/49 OR CARCINOMA 1/50 3/50 1/49 1/49 COMBINED 2/50 4/50 7/49 4/49
|
Neoplastic Lesions
|
No
|
TR-395
|
57-66-9 |
Probenecid |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-395
|
57-66-9 |
Probenecid |
Rats |
F344/N |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-395
|
57-66-9 |
Probenecid |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 3/48 2/49 14/49, CARCINOMA 2/48 2/49 3/49, COMBINED 5/48 3/49 16/49
|
Neoplastic Lesions
|
No
|
TR-515
|
57018-52-7 |
Propylene glycol mono-t-butyl ether |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA (STANDARD EVALUATION) 1/50 1/50 3/49 2/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 5/49 4/50 ADENOMA OR CARCINOMA (STANDARD EVALUATION) 1/50 1/50 3/49 3/50 (STANDARD AND EXTENDED EVALUATIONS COMBINED) 1/50 2/50 5/49 5/50
|
May Have Been Related
|
No
|
TR-515
|
57018-52-7 |
Propylene glycol mono-t-butyl ether |
Rats |
F344/N |
Male |
Inhalation |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 3/50 0/50 2/49 6/50
|
May Have Been Related
|
Yes
|
TR-515
|
57018-52-7 |
Propylene glycol mono-t-butyl ether |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/49 8/50 10/50 37/49 CARCINOMA 4/49 8/50 7/50 10/49 COMBINED 18/49 14/50 16/50 41/49 HEPATOBLASTOMA 0/49 0/50 0/50 2/49
|
Neoplastic Lesions
|
Yes
|
TR-515
|
57018-52-7 |
Propylene glycol mono-t-butyl ether |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 23/49 26/50 36/50 CARCINOMA 9/50 8/49 13/50 11/50 COMBINED 25/50 26/49 33/50 41/50 HEPATOBLASTOMA 0/50 0/49 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-563
|
89-82-7 |
Pulegone |
Mice |
B6C3F1/N |
Female |
Gavage |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Osteoma or osteosarcoma: 0/49 0/50 3/50 1/50
|
May Have Been Related
|
Yes
|
TR-563
|
89-82-7 |
Pulegone |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Hepatocellular: Adenoma 13/49 15/50 13/50 27/50 adenoma, carcinoma or hepatoblastoma 17/49 15/50 15/50 33/50
|
Neoplastic Lesions
|
Yes
|
TR-563
|
89-82-7 |
Pulegone |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Hepatocellular: Adenoma 22/50 31/50 35/50 28/50 adenoma, carcinoma, or hepatoblastoma 29/50 37/50 42/50 36/50
|
Neoplastic Lesions
|
No
|
TR-563
|
89-82-7 |
Pulegone |
Rats |
F344/N |
Female |
Gavage |
Urinary Bladder
|
Some Evidence |
Some Evidence |
Papilloma 0/50 0/49 1/50 3/47 papilloma or carcinoma 0/50 0/49 1/50 5/47
|
Neoplastic Lesions
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Equivocal Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 12/50 16/50 22/50 23/50
|
May Have Been Related
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
F344/N |
Male |
Dosed-Water |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 0/48 2/50 6/49 COMBINED 1/50 1/48 2/50 6/49; (SINGLE AND STEP SECTIONS) ADENOMA 2/50 3/48 6/50 10/49 COMBINED 2/50 4/48 6/50 10/49
|
Neoplastic Lesions
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
Wistar |
Male |
Dosed-Water |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
(SINGLE SECTIONS) ADENOMA 1/50 0/48 2/50 6/49 COMBINED 1/50 1/48 2/50 6/49; (SINGLE AND STEP SECTIONS) ADENOMA 2/50 3/48 6/50 10/49 COMBINED 2/50 4/48 6/50 10/49
|
Neoplastic Lesions
|
Yes
|
TR-470
|
110-86-1 |
Pyridine |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 37/49 39/50 43/50 34/50, CARCINOMA 13/49 23/50 33/50 41/50, HEPATOBLASTOMA 1/49 2/50 9/50 16/50 COMBINED 41/49, 42/50, 45/50, 44/50
|
Neoplastic Lesions
|
Yes
|
TR-470
|
110-86-1 |
Pyridine |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 29/50 40/50 34/49 39/50, CARCINOMA 15/50 35/50 41/49 40/50, HEPATOBLASTOMA 2/50 18/50 22/49 15/50; COMBINED 38/50, 47/50, 46/49, 47/50
|
Neoplastic Lesions
|
No
|
TR-470
|
110-86-1 |
Pyridine |
Rats |
Wistar |
Male |
Dosed-Water |
Testis
|
Equivocal Evidence |
Equivocal Evidence |
INTERSTITIAL CELL ADEMONA 5/50 6/49 4/49 12/50
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 12/50 8/50 13/50 18/50 18/50 14/50
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
Hematopoietic System: MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 2/50 9/50
|
Neoplastic Lesions
|
Yes
|
TR-508
|
23246-96-0 |
Riddelliine |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 2/50 1/50 0/50 2/50 31/50
|
Neoplastic Lesions
|
Yes
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 0/50 3/50 38/50; ADENOMA 1/50 0/50 0/50 0/50 1/50 7/50
|
Neoplastic Lesions
|
Yes
|
TR-508
|
23246-96-0 |
Riddelliine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 43/50; ADENOMA 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-508
|
23246-96-0 |
Riddelliine |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/50 COMBINED 2/50 13/50
|
Neoplastic Lesions
|
No
|
TR-457
|
599-79-1 |
Salicylazosulfapyridine |
Rats |
F344/N |
Female |
Gavage |
Kidney Transitional Cell
|
Some Evidence |
Some Evidence |
PAPILLOMA 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-457
|
599-79-1 |
Salicylazosulfapyridine |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 12/50 28/50 25/50 28/49 OR CARCINOMA 2/50 10/50 10/50 9/49 COMBINED 14/50 32/50 28/50 29/49
|
Neoplastic Lesions
|
Yes
|
TR-457
|
599-79-1 |
Salicylazosulfapyridine |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 13/50 32/50 28/50 42/50 OR CARCINOMA 13/50 15/50 23/50 8/50 COMBINED 24/50 38/50 38/50 44/50
|
Neoplastic Lesions
|
No
|
TR-457
|
599-79-1 |
Salicylazosulfapyridine |
Rats |
F344/N |
Female |
Gavage |
Urinary Bladder
|
Some Evidence |
Some Evidence |
TRANSITIONAL CELL PAPILLOMA 0/49 0/50 2/50 0/50
|
Neoplastic Lesions
|
No
|
TR-457
|
599-79-1 |
Salicylazosulfapyridine |
Rats |
F344/N |
Male |
Gavage |
Urinary Bladder
|
Some Evidence |
Some Evidence |
(CORE STUDY) TRANSITIONAL CELL PAPILLOMA 0/50 0/49 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-194
|
7446-34-6 |
Selenium sulfide |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-587
|
79-94-7 |
Tetrabromobisphenol A |
Mice |
B6C3F1/N |
Male |
Gavage |
All Organs
|
Some Evidence |
Equivocal Evidence |
(Hemangiosarcoma) 1/50 5/50 8/50
|
May Have Been Related
|
No
|
TR-587
|
79-94-7 |
Tetrabromobisphenol A |
Mice |
B6C3F1/N |
Male |
Gavage |
Intestines (Large)
|
Some Evidence |
Equivocal Evidence |
(cecum or colon) adenoma or carcinoma 0/50 0/50 3/50
|
May Have Been Related
|
Yes
|
TR-587
|
79-94-7 |
Tetrabromobisphenol A |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
hepatoblastoma 2/50 11/50 8/50
|
Neoplastic Lesions
|
No
|
TR-587
|
79-94-7 |
Tetrabromobisphenol A |
Rats |
Wistar Han |
Male |
Gavage |
Testis
|
Equivocal Evidence |
Equivocal Evidence |
interstitial cell, adenoma 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-587
|
79-94-7 |
Tetrabromobisphenol A |
Rats |
Wistar Han |
Female |
Gavage |
Uterus
|
Clear Evidence |
Clear Evidence |
adenoma (original transverse review) 0/50 0/50 3/50 4/50 adenocarcinoma (original transverse review) 3/50 3/50 8/50 9/50 )original transverse and residual longitudinal reviews, combined) 4/50 10/50 15/50 16/50 malignant mixed Müllerian tumor (original transverse review) 0/50 4/50 0/50 2/50 adenoma, adenocarcinoma, or malignant mixed Müllerian tumor (original transverse review) 3/50 7/50 11/50 13/50 )original transverse and residual longitudinal reviews, combined) 6/50 11/50 16/50 19/50
|
Neoplastic Lesions
|
No
|
TR-131
|
72-54-8 |
Tetrachlorodiphenylethane |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-131
|
72-54-8 |
Tetrachlorodiphenylethane |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-131
|
72-54-8 |
Tetrachlorodiphenylethane |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-131
|
72-54-8 |
Tetrachlorodiphenylethane |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-013
|
127-18-4 |
Tetrachloroethylene |
Rats |
Osborne Mendel |
Female |
Gavage |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-013
|
127-18-4 |
Tetrachloroethylene |
Rats |
Osborne Mendel |
Male |
Gavage |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 28/50 37/50 37/50
|
Neoplastic Lesions
|
No
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Rats |
F344/N |
Female |
Inhalation |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 18/50 30/50 29/50
|
Neoplastic Lesions
|
No
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 3/49 2/50 OR ADENOCARCINOMA 0/49 0/49 2/50 COMBINED 1/49 3/49 4/50
|
Neoplastic Lesions
|
Yes
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/48 13/50 36/50
|
Neoplastic Lesions
|
Yes
|
TR-311
|
127-18-4 |
Tetrachloroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/49 8/49 18/50; CARCINOMA 7/49 25/49 26/50
|
Neoplastic Lesions
|
Yes
|
TR-013
|
127-18-4 |
Tetrachloroethylene |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-013
|
127-18-4 |
Tetrachloroethylene |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-033
|
961-11-5 |
Tetrachlorvinphos |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-033
|
961-11-5 |
Tetrachlorvinphos |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Adrenal Gland Cortex
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
Yes
|
TR-033
|
961-11-5 |
Tetrachlorvinphos |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(NEOPLASTIC NODULE)
|
Neoplastic Lesions
|
Yes
|
TR-033
|
961-11-5 |
Tetrachlorvinphos |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-033
|
961-11-5 |
Tetrachlorvinphos |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Thyroid Gland C-Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA: 34/50 43/50 38/50 31/50
|
May Have Been Related
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HISTIOCYTIC SARCOMA 1/48 21/48 19/47 18/48
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
HISTIOCYTIC SARCOMA 0/48 12/48 7/48 7/48
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA: 16/50 31/50 23/50 36/50
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
SINGLE SECTIONS: ADENOMA 0/50 3/50 1/50 3/50 OR CARCINOMA 0/50 0/50 0/50 2/50 COMBINED 0/50 3/50 1/50 5/50; SINGLE AND STEP SECTIONS: ADENOMA 0/50 3/50 3/50 8/50 OR CARCINOMA 0/50 0/50 0/50 3/50 COMBINED 0/50 3/50 3/50 10/50
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
SINGLE SECTIONS: ADENOMA 0/50 0/50 6/50 3/50 OR CARCINOMA 1/50 0/50 2/50 0/50 COMBINED 1/50 0/50 6/50 3/50; SINGLE AND STEP SECTIONS: ADENOMA 2/50 4/50 9/50 13/50 OR CARCINOMA 1/50 1/50 2/50 0/50 COMBINED 3/50 5/50 9/50 13/50
|
Neoplastic Lesions
|
Yes
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 15/48 17/48 20/47 15/47 OR CARCINOMA 4/48 28/48 22/47 20/47 COMBINED 17/48 33/48 29/47 28/47
|
Neoplastic Lesions
|
Yes
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/48 17/48 12/48 20/48 OR CARCINOMA 11/48 20/48 33/48 26/48 COMBINED 26/48 34/48 39/48 35/48
|
Neoplastic Lesions
|
Yes
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 4/50 5/50 6/50 OR CARCINOMA 0/50 4/50 9/50 2/50 COMBINED 0/50 7/50 12/50 8/50
|
Neoplastic Lesions
|
Yes
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/50 8/50 5/50 OR CARCINOMA 1/50 1/50 10/50 3/50 COMBINED 4/50 7/50 15/50 8/50
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Equivocal Evidence |
INTERSTITIAL CELL ADENOMA 39/50 40/50 48/50 47/50
|
May Have Been Related
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Liver)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/48 5/48 2/47 1/47 OR HEMANGIOSARCOMA 0/48 27/48 27/47 34/47 COMBINED 0/48 31/48 28/47 35/47
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Liver)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/48 10/48 5/48 2/48 OR HEMANGIOSARCOMA 0/48 21/48 27/48 37/48 COMBINED 0/48 26/48 30/48 38/48
|
Neoplastic Lesions
|
No
|
TR-450
|
116-14-3 |
Tetrafluoroethylene |
Rats |
F344/N |
Female |
Inhalation |
Vascular System (Liver)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 5/50 1/50
|
Neoplastic Lesions
|
No
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Mice |
B6C3F1 |
Male |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Rats |
F344/N |
Female |
Inhalation |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 1/50 4/50 3/50 OR CARCINOMA 0/50 0/50 0/50 2/50 COMBINED 1/50 1/50 4/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-475
|
109-99-9 |
Tetrahydrofuran |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 12/50 17/50 18/50 31/48 OR CARCINOMA 6/50 10/50 10/50 16/48 COMBINED 17/50 24/50 26/50 41/48
|
Neoplastic Lesions
|
No
|
TR-561
|
119-64-2 |
Tetralin |
Rats |
F344/N |
Male |
Inhalation |
Kidney
|
Some Evidence |
Some Evidence |
Cortical renal tubule adenoma (standard evaluation) 0/50 1/50 1/50 2/50 standard and extended combined 0/50 3/50 2/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-561
|
119-64-2 |
Tetralin |
Rats |
F344/N |
Female |
Inhalation |
Liver
|
Some Evidence |
Some Evidence |
Adenoma 0/50 0/50 0/50 3/50 adenoma or carcinoma 0/50 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-561
|
119-64-2 |
Tetralin |
Mice |
B6C3F1/N |
Female |
Inhalation |
Spleen
|
Equivocal Evidence |
Equivocal Evidence |
Hemangiosarcoma 1/50 0/50 1/50 4/50
|
May Have Been Related
|
No
|
TR-561
|
119-64-2 |
Tetralin |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Some Evidence |
Equivocal Evidence |
Adenoma, interstitial cell 29/50 39/50 31/50 41/50
|
May Have Been Related
|
No
|
TR-561
|
119-64-2 |
Tetralin |
Rats |
F344/N |
Female |
Inhalation |
Uterus
|
Some Evidence |
Some Evidence |
Stromal polyp 6/50 10/50 9/50 17/50
|
Neoplastic Lesions
|
Yes
|
TR-037
|
8001-35-2 |
Toxaphene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-037
|
8001-35-2 |
Toxaphene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-037
|
8001-35-2 |
Toxaphene |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-037
|
8001-35-2 |
Toxaphene |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Equivocal Evidence |
Equivocal |
ADENOMA, ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Adrenal Gland Cortex
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/52 2/55 1/53 0/53 1/53 1/52 4/53 3/50
|
May Have Been Related
|
Yes
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
CHOLANGIOMA 0/53 0/55 0/53 0/53 0/53 1/51 1/53 0/50
|
May Have Been Related
|
Yes
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/55 1/53 0/53 5/53 6/51 22/53 2/50 OR ADENOMA 1/53 2/55 1/53 0/53 2/53 4/51 7/53 0/50 OR HEPATOCHOLANGIOMA 0/53 0/55 0/53 0/53 0/53 0/51 3/53 0/50
|
Neoplastic Lesions
|
No
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/55 0/53 0/53 1/53 11/51 35/51 0/50 OR SQUAMOUS CELL CARCINOMA 0/53 0/55 0/53 0/53 0/53 1/51 2/51 0/50
|
Neoplastic Lesions
|
No
|
TR-520
|
57465-28-8 |
Toxic equivalency factor evaluation ((PCB 126) 3,3',4,4',5-pentachlorobiphenyl) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQUAMOUS CELL CARINOMA (ORAL MUCOSA) 0/53 1/55 1/53 1/53 2/53 2/53 7/53 2/50
|
Neoplastic Lesions
|
Yes
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/53 1/52 9/52 30/51 HEPATOCHOLANGIOMA 0/53 0/53 0/52 2/52 6/51 ADENOMA 0/53 0/53 3/52 5/52 27/51
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/52 1/53 11/52
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA (GINGIVAL) 0/53 0/53 2/53 5/53 9/53
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 1/53 1/52 3/52 1/50 ADENOMA OR CARCINOMA 0/53 1/53 1/52 4 /52 2/50
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 1/53 1/53 1/53 4/53 0/53
|
May Have Been Related
|
Yes
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 1/53 1/53 1/53 11/51 OR CHOLANGIOCARCINOMA 0/53 0/53 2/53 7/53 9/51
|
Neoplastic Lesions
|
No
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/53 2/53 20/53
|
Neoplastic Lesions
|
No
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/52 1/53 2/53 2/53 0/51
|
May Have Been Related
|
Yes
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 0/52 0/51 0/52 0/52 3/52 36/49 29/49 adenoma 0/52 1/51 1/52 4/52 12/52 24/49 1/49 hepatocholangioma 0/52 0/51 0/52 0/52 0/52 4/49 0/49
|
Neoplastic Lesions
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/51 0/52 0/52 0/52 0/52 20/50 0/50
|
Neoplastic Lesions
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
Adenoma 0/52 0/52 0/52 2/52 3/52 1/47 0/49 adenoma or carcinoma 0/50 0/52 0/52 2/52 3/52 2/47 0/49
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus
|
Clear Evidence |
Equivocal Evidence |
Squamous cell carcinoma: 0/52 0/52 3/52 1/52 1/52 0/52 1/50
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus
|
Clear Evidence |
Clear Evidence |
Carcinoma 2/52 2/52 1/52 3/52 4/52 3/52 11/50
|
Neoplastic Lesions
|
Yes
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
HEPATOCHOLANGIOMA 0/53 0/51 0/53 1/53 1/53 1/65 1/50 CHOLANGIOMA 0/53 0/51 0/53 1/53 0/53 0/65 0/50
|
May Have Been Related
|
Yes
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/51 5/53 19/53 28/53 12/65 19/50 ADENOMA 2/53 1/51 0/53 4/53 17/53 5/65 1/50 CARCINOMA 0/53 0/51 0/53 0/53 1/53 0/65 0/50
|
Neoplastic Lesions
|
No
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/51 0/53 20/53 49/53 41/66 12/50
|
Neoplastic Lesions
|
No
|
TR-531
|
TEFPCBMIX |
Toxic equivalency factor evaluation (PCB Mixture; PCB 126/PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 1/51 2/53 4/53 0/53 1/66 1/50
|
Neoplastic Lesions
|
Yes
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/53 0/53 1/53 0/52 2/53 4/53 1/50 OR CHOLANGIOCARCINOMA 0/53 0/53 0/53 1/52 1/53 2/53 0/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Some Evidence |
Equivocal Evidence |
CYSTIC KERATINIZING EPITHELIOMA (MULTIPLE) 0/53 0/53 0/53 0/53 0/53 1/52 0/50
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Some Evidence |
Some Evidence |
(ORAL MUCOSA) GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 2/53 1/53 0/53 1/53 3/53 3/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/53 0/53 0/53 0/52 2/52 0/52 2/49
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 1/53 1/53 0/53 1/53 5/53 2/53 1/50
|
May Have Been Related
|
Yes
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
HEPATOCHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 2/53 0/50 OR CHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 0/53 1/50
|
May Have Been Related
|
Yes
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 0/54 0/53 0/53 1/53 13/53 2/50 OR CHOLANGIOCARCINOMA 0/53 0/54 0/53 1/53 4/53 25/53 2/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/54 0/53 0/52 0/53 9/52 0/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQAMOUS CELL CARCINOMA (ORAL MUCOSA) 1/53 2/54 1/53 0/53 4/53 10/53 5/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/51 0/54 0/52 0/53 0/52 3/51 1/49
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/53 0/54 0/53 0/53 5/53 0/53 2/50
|
Neoplastic Lesions
|
No
|
TR-420
|
396-01-0 |
Triamterene |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 6/50 4/50 3/49
|
Neoplastic Lesions
|
Yes
|
TR-420
|
396-01-0 |
Triamterene |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
(FIRST STUDY) ADENOMA 10/50 22/50 23/50 36/60 OR CARCINOMA 4/50 4/50 3/50 8/60 COMBINED 13/50 26/50 25/50 37/60; (SECOND STUDY) ADENOMA 7/50 28/51 OR CARCINOMA 5/50 11/51 COMBINED 10/50 31/51
|
Neoplastic Lesions
|
Yes
|
TR-420
|
396-01-0 |
Triamterene |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
(FIRST STUDY) ADENOMA 17/50 22/50 19/50 20/60 OR CARCINOMA 5/50 7/50 3/50 13/60 COMBINED 20/50 26/50 19/50 29/60; (SECOND STUDY) ADENOMA 21/50 36/50 OR CARCINOMA 9/50 11/50 COMBINED 25/50 38/50
|
Neoplastic Lesions
|
No
|
TR-243
|
79-01-6 |
Trichloroethylene |
Rats |
F344/N |
Male |
Gavage |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-243
|
79-01-6 |
Trichloroethylene |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-002
|
79-01-6 |
Trichloroethylene |
Rats |
Osborne Mendel |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-002
|
79-01-6 |
Trichloroethylene |
Rats |
Osborne Mendel |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-002
|
79-01-6 |
Trichloroethylene |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-243
|
79-01-6 |
Trichloroethylene |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
ADENOMA 2/48 8/49; CARCINOMA 2/48 13/49
|
Neoplastic Lesions
|
Yes
|
TR-243
|
79-01-6 |
Trichloroethylene |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 8/48 30/50
|
Neoplastic Lesions
|
Yes
|
TR-002
|
79-01-6 |
Trichloroethylene |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-518
|
102-71-6 |
Triethanolamine |
Mice |
B6C3F1/N |
Male |
Topical Application |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
HEMANGIOSARCOMA 1/50 0/50 6/50 1/50
|
May Have Been Related
|
Yes
|
TR-518
|
102-71-6 |
Triethanolamine |
Mice |
B6C3F1/N |
Female |
Topical Application |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 9/50 18/50 20/50 33/50 COMBINED 12/50 23/50 24/50 34/50
|
Neoplastic Lesions
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-576
|
15625-89-5 |
Trimethylolpropane triacrylate |
Mice |
B6C3F1 |
Female |
Topical Application |
Liver
|
Some Evidence |
Some Evidence |
hepatoblastoma 0/50, 4/50, 0/50, 3/50; hepatocholangiocarcinoma 0/50, 0/50, 1/50, 2/50
|
Neoplastic Lesions
|
No
|
TR-576
|
15625-89-5 |
Trimethylolpropane triacrylate |
Rats |
F344/N |
Male |
Topical Application |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Equivocal Evidence |
Equivocal Evidence |
Malignant Mesothelioma 0/50, 2/50, 2/50, 5/50
|
May Have Been Related
|
No
|
TR-576
|
15625-89-5 |
Trimethylolpropane triacrylate |
Mice |
B6C3F1 |
Female |
Topical Application |
Uterus
|
Some Evidence |
Some Evidence |
stromal polyp or stromal sarcoma 0/50, 1/50, 2/50, 6/50
|
Neoplastic Lesions
|
No
|
TR-274
|
78-42-2 |
tris(2-Ethylhexyl)phosphate |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-274
|
78-42-2 |
tris(2-Ethylhexyl)phosphate |
Rats |
F344/N |
Male |
Gavage |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
PHEOCHROMOCYTOMA 2/50 9/50 12/50
|
Neoplastic Lesions
|
Yes
|
TR-274
|
78-42-2 |
tris(2-Ethylhexyl)phosphate |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
CARCINOMA 0/48 4/50 7/50
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA, ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-602
|
13674-84-5 |
Tris(Chloropropyl) Phosphate (TCPP) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
hepatocellular adenoma (1/50, 3/50, 0/50, 3/50, 3/50)
|
May Have Been Related
|
Yes
|
TR-602
|
13674-84-5 |
Tris(Chloropropyl) Phosphate (TCPP) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (includes multiple) (11/50, 5/50, 13/50, 23/50); hepatocellular carcinoma (includes multiple) (1/50, 2/50, 5/50, 10/50); hepatocellular adenoma or carcinoma (combined) (12/50, 7/50, 16/50, 29/50)
|
Neoplastic Lesions
|
Yes
|
TR-602
|
13674-84-5 |
Tris(Chloropropyl) Phosphate (TCPP) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
hepatocellular carcinoma (includes multiple) (5/50, 14/50, 17/50, 14/50)
|
Neoplastic Lesions
|
Yes
|
TR-602
|
13674-84-5 |
Tris(Chloropropyl) Phosphate (TCPP) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
hepatocellular adenoma or carcinoma (combined) (1/50, 0/50, 1/50, 7/50, 6/49)
|
Neoplastic Lesions
|
No
|
TR-602
|
13674-84-5 |
Tris(Chloropropyl) Phosphate (TCPP) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Some Evidence |
Some Evidence |
adenoma or adenocarcinoma (combined) (3/50, 4/50, 6/50, 8/49, 9/50)
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 1/47 5/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47
|
Neoplastic Lesions
|
Yes
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 0/46 2/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/45 1/47 4/46
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 0/48 2/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48
|
Neoplastic Lesions
|
Yes
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
All Organs
|
Some Evidence |
Equivocal Evidence |
malignant mesothelioma 0/50 1/50 1/50 0/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
hemangioma or hemangiosarcoma 4/50 6/50 6/50 11/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
All Organs
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/50 12/50 28/50 23/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
All Organs
|
Some Evidence |
Some Evidence |
mononuclear cell leukemia 10/50 11/50 13/50 25/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
(Duodenum, Jejunum, or Ileum): carcinoma 1/50 1/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Male |
Inhalation |
Kidney
|
Clear Evidence |
Clear Evidence |
renal tubule adenoma 0/50 5/50 19/50 10/50 renal tubule carcinoma 0/50 7/50 31/50 18/50 renal tubule adenoma or carcinoma 0/50 11/50 37/50 27/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
Kidney
|
Clear Evidence |
Clear Evidence |
renal tubule carcinoma 0/50 2/50 1/49 1/50
|
Neoplastic Lesions
|
Yes
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Male |
Inhalation |
Liver
|
Clear Evidence |
Equivocal Evidence |
hepatocholangiocarcionoma 1/50 2/50 2/50 3/50
|
May Have Been Related
|
Yes
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 25/50 21/50 36/50 29/50 hepatocellular carcinoma 8/50 14/50 12/50 17/50 hepatocellular adenoma or carcinoma 28/50 30/50 37/50 38/50 hepatocholangiocarcinoma 0/50 1/50 1/50 2/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Mice |
B6C3F1/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
alveolar/bronchiolar carcinoma 1/50 2/50 7/50 5/49
|
May Have Been Related
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Male |
Inhalation |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
respiratory epithelium, adenoma 0/49 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-582
|
75-35-4 |
Vinylidene Chloride |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland C-Cell
|
Some Evidence |
Some Evidence |
adenoma 3/50 4/50 6/48 11/50; carcinoma 0/50 6/50 2/48 2/50 adenoma or carcinoma 3/50 10/50 8/48 13/50
|
Neoplastic Lesions
|
No
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
Adenoma 0/50 0/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
Adenoma 0/50 2/50 0/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Equivocal Evidence |
Adenoma 0/50 0/50 0/50 3/50
|
May Have Been Related
|
Yes
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Equivocal Evidence |
Adenoma 2/50 0/50 3/50 4/50
|
May Have Been Related
|
Yes
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 27/50 48/50 44/50 46/50 carcinoma 14/50 23/50 26/50 20/50 adenoma or carcinoma 31/50 49/50 46/50 46/50
|
Neoplastic Lesions
|
Yes
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
Adenoma 27/50 40/50 40/50 31/50 carcinoma 19/50 25/50 36/50 45/50 adenoma or carcinoma 34/50 44/50 49/50 49/50 hepatoblastoma 4/50 11/50 28/50 34/50
|
Neoplastic Lesions
|
No
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
Fibroadenoma, multiple 22/50 24/50 43/50 38/50
|
Neoplastic Lesions
|
No
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Rats |
F344/N |
Male |
Dosed-Water |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
Malignant Mesothelioma 1/50 5/50 10/50 6/50
|
Neoplastic Lesions
|
No
|
TR-549
|
5589-96-8 |
Water disinfection byproducts (Bromochloroacetic acid) |
Rats |
F344/N |
Male |
Dosed-Water |
Pancreas Islet Cell
|
Clear Evidence |
Equivocal Evidence |
Adenoma 3/50 4/50 9/50 3/50
|
May Have Been Related
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
All Organs
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/50 12/50 18/50 37/50
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Female |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 3/50 1/50
|
May Have Been Related
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 4/50 3/50
|
May Have Been Related
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 6/50 11/50 14/49 19/51 adenoma or carcinoma 6/50 11/50 14/49 20/51
|
Neoplastic Lesions
|
Yes
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 33/49 42/50 42/49 44/50 hepatocellular carcinoma 9/49 17/50 22/49 26/50 hepatoblastoma 0/49 1/50 4/49 6/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 36/49 44/50 43/49 46/50
|
Neoplastic Lesions
|
Yes
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 12/50 22/50 27/49 39/51 hepatoblastoma 4/50 24/50 40/49 34/51
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 28/50 47/50 47/50 39/50 carcinoma 0/50 1/50 3/50 8/50 fibroadenoma, adenoma, or carcinoma 28/50 47/50 48/50 42/50
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
(oral mucosa and tongue): squamous cell papilloma or squamous cell carcinoma 1/50 0/50 3/50 3/50
|
May Have Been Related
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma, keratoacanthoma, sebaceous gland adenoma, basal cell adenoma, basal cell carcinoma, or squamous cell carcinoma 9/50 7/50 15/50 21/50
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(subcutaneous tissue): fibroma 4/50 6/50 10/50 15/50
|
Neoplastic Lesions
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Some Evidence |
Some Evidence |
MONONUCLEAR CELL LEUKEMIA (ALL ORGANS) 11/50 13/50 16/50 22/50
|
Neoplastic Lesions
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Rats |
F344/N |
Male |
Dosed-Water |
Hematopoietic System
|
Some Evidence |
Some Evidence |
MALIGNANT MESOTHELIOMA (ALL ORGANS) 3/50 1/50 0/50 10/50
|
Neoplastic Lesions
|
Yes
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 19/49 26/50 32/50 35/49 CARCINOMA 3/49 3/50 12/50 8/49 COMBINED 22/49 28/50 37/50 37/49
|
Neoplastic Lesions
|
Yes
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/49 37/50 37/50 42/50 CARCINOMA 14/49 9/50 19/50 26/50 COMBINED 28/49 41/50 42/50 47/50 HEPATOBLASTOMA 0/49 4/50 6/50 18/50
|
Neoplastic Lesions
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 3/50 3/50 6/50 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/50 5/50 5/50 7/50
|
May Have Been Related
|
No
|
TR-537
|
631-64-1 |
Water disinfection byproducts (Dibromoacetic acid) |
Mice |
B6C3F1 |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/49 5/50 17/50 12/50 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 12/49 12/50 22/50 17/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma 1/50 0/50 5/50 14/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 1/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Male |
Dosed-Water |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
Adenoma 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Equivocal Evidence |
Hepatoblastoma 1/50 7/50 3/50 2/50 adenoma, carcinoma or hepatoblastoma 37/50 46/50 43/50 42/50
|
May Have Been Related
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Some Evidence |
Some Evidence |
Squamous cell papilloma 1/50 0/50 4/50 0/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Some Evidence |
Equivocal Evidence |
Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 0/50 0/50 3/50 4/50
|
May Have Been Related
|
No
|
TR-235
|
17924-92-4 |
Zearalenone |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-235
|
17924-92-4 |
Zearalenone |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-235
|
17924-92-4 |
Zearalenone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
ADENOMA 0/50 2/49 7/49
|
Neoplastic Lesions
|
No
|
TR-235
|
17924-92-4 |
Zearalenone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Pituitary Gland
|
Positive |
Positive |
ADENOMA 3/46 2/43 13/42
|
Neoplastic Lesions
|
No
|
TR-235
|
17924-92-4 |
Zearalenone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Pituitary Gland
|
Positive |
Positive |
ADENOMA 0/40 4/45 6/44
|
Neoplastic Lesions
|